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Foreword
We are pleased to present the key findings of the European Union’s research project on Driving 
Under the Influence of Drugs, Alcohol and Medicines, known as the DRUID project. The project was 
set up by the European Commission’s Directorate-General for Energy and Transport and comprised 
seven work packages: experimental studies, epidemiological studies, enforcement, classification (of 
medicines), rehabilitation, withdrawal (of driving licence), and dissemination and guidelines. Over 
5 years of work across 18 countries, the project has produced some 50 reports, each one 
contributing key evidence to road safety policy.
This thematic paper has been prepared by the EMCDDA with the DRUID project coordinator and 
work package leaders, and is based on the project’s reports and findings. By publishing this paper, 
the EMCDDA aims to bring the main results of the DRUID project to a wider audience.
The EMCDDA is proud to be associated with this seminal work and, although the project itself is 
now complete, wishes to support its legacy and its peerless contribution to common European 
standards in drug-driving research. We would like to thank all DRUID partners and especially the 
work package leaders for their important contribution to the project’s success, and also the peer 
reviewers whose expert knowledge enhanced the quality of the deliverables. It would not have 
been possible to complete this project without the support and close collaboration of the European 
Commission and especially that of the project officers Joel Valmain and Maria-Cristina Marolda.
We believe the findings of this project will contribute to enhancing the safety of citizens on the 
roads of Europe, today and in the future.
Wolfgang Götz 
Director, EMCDDA
Horst Schulze 
DRUID project coordinator
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Summary
Roadside surveys conducted in 13 countries across Europe, in which blood or oral fluid samples 
from 50 000 drivers were analysed, revealed that alcohol was present in 3.48 %, illicit drugs in 
1.90 %, medicines in 1.36 %, combinations of drugs or medicines in 0.39 % and alcohol combined 
with drugs or medicines in 0.37 %. However, there were large differences among the mean values 
in the regions of northern, eastern, southern and western Europe. Although the absolute numbers 
were quite low, the prevalence of alcohol, cocaine, cannabis and combined substance use was 
higher in southern Europe, and to some extent in western Europe, than in the other two regions, 
whereas medicinal opioids and ‘z-drugs’, such as zopiclone and zolpidem, were detected more in 
northern Europe.
Studies of hospitalised, seriously injured car drivers were conducted in six countries, and studies of 
car drivers killed in accidents took place in four countries. Among the injured or killed drivers, the 
most commonly consumed substance was alcohol alone, followed by alcohol combined with 
another substance. The use of illicit drugs alone was not frequently detected. After alcohol, the most 
frequently found substance among injured drivers was tetrahydrocannabinol (THC) followed by 
benzodiazepines, whereas, among drivers killed in accidents, it was benzodiazepines.
The results of the roadside surveys and the hospital surveys were combined in a case–control study 
to calculate the relative risk of being seriously injured or killed in a traffic accident. The project 
assigned the investigated substances to one of four groups, according to whether the increased risk 
was considered to be slight, medium, considerable or high. The findings showed that alcohol is still 
one of the most dangerous psychoactive substances used by drivers. The biggest risk for a driver of 
being seriously injured or dying in a traffic accident arises from high blood alcohol levels or from 
combinations of alcohol, drugs or medicines.
Most of the seriously injured or killed drivers who tested positive for alcohol were severely 
intoxicated. However, results of interviews in two countries showed that problem drinkers do not 
believe that alcohol impairs their driving. Intensive drug users were more likely than moderate drug 
users to drive under the influence, with the latter taking a more responsible approach to driving 
under the influence of drugs.
Alcohol and drugs were detected more often in male drivers. Medicines were detected mainly in 
middle-aged and older female drivers, but, among drivers seriously injured or killed in accidents, 
medicines were more often found in male drivers in the same age ranges, often in combination with 
other substances.
Experimental studies suggested that the illicit stimulants d-amphetamine, MDMA (‘ecstasy’) and 
cocaine have no negative influence on fitness to drive, but studies of drivers injured and killed in 
accidents found considerably higher median drug levels for stimulants, and such levels may have 
detrimental effects on self-perception, critical judgement and risk-taking. A night of sleep 
deprivation alone impairs performance to a similar degree to the 0.8 g/l blood alcohol 
concentration (BAC), i.e. higher than the common legal driving limit of 0.5 g/l, and MDMA in 
combination with alcohol (or sleep deprivation) causes dramatic impairment of driving 
emcdda.europa.eu
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performance; stimulants do not compensate for alcohol use or sleep deprivation. A few medicines 
can cause impairment of which the patient is unaware.
A number of recommendations were made to update the wording of the 1991 European Council 
Directive on Driving Licences, referring to licence withdrawal due to consumption of drugs and 
psychoactive substances.
Very few public information campaigns regarding drug-driving were evaluated for their impact — 
and some of them evaluated only awareness of the campaign, rather than if it changed driver 
behaviour.
Psychoactive medicines on the EU market were classified into four categories depending on their 
influence on fitness to drive, and it was demonstrated that a pictogram on the package indicating 
the risk when driving was effective in changing patients’ intended behaviour. In collaboration with 
experts of the Pharmacovigilance Working Party of the European Medicines Agency, 
recommendations could be presented for improving the package information leaflet for category II 
(moderately impairing) and category III (severely impairing) medicines. It was also shown that a 
software package could assist physicians and pharmacists in giving advice to patients when 
prescribing and dispensing such medicines, respectively.
Legal limits, consistently enforced, are the single most effective approach to combat drink-driving. 
The maximum standard legal limit should be 0.5 g/l BAC, and stricter limits for certain risk groups 
(novice drivers, professional drivers) should be considered. As mixed intoxication with other 
substances poses a greater risk, the alcohol limit must be lower in such cases.
To combat drug-driving, most countries either operate a zero tolerance policy or take into account 
degree of impairment, sometimes in a two-tier system. Legal limits may be set low, at the limit of 
detection, or higher to take effects into consideration. For example, while the project set a detection 
limit of 1 ng/ml in whole blood for THC in the roadside surveys, it was found that 2 ng/ml THC in 
whole blood (3.8 ng/ml THC in serum) seems to cause impairment equivalent to 0.5 g/l BAC. Such 
equivalents could not be calculated for other drugs. It is not realistic to develop cut-off limits for all 
substances.
Regarding driving under the influence of medicines, a legal limit for patients undergoing long-term 
treatment is inappropriate; sanctions should be based on degree of impairment.
None of the roadside oral fluid testing devices achieved the target value of 80 % sensitivity, 
specificity and accuracy for all the individual substances tested. Thus, when considering the 
suitability of a device, the type and prevalence of drugs within the target population should be 
considered. An evaluation of a checklist of clinical signs of impairment, such as bloodshot eyes, did 
not give promising results; more experience and better training of police officers may improve this.
In the near future, analysis of dried blood spots could be a much quicker and less invasive method 
of proving an offence than taking a sample of whole blood from a driver using a syringe. Transport 
and storage of dried blood spots are also much easier than for whole blood.
emcdda.europa.eu
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A cost–benefit evaluation found that increased enforcement of drug-driving sanctions, based on 
roadside oral fluid screening, is potentially cost-beneficial, particularly for countries where the level 
of enforcement is currently low. However, increasing drug-driving enforcement at the expense of a 
reduction in drink-driving enforcement may actually decrease the positive impact on road safety. As 
the risk and share of injuries is higher for alcohol, targeting driving under the influence of alcohol 
should always be the first priority of law enforcers.
Withdrawal of the driving licence is an effective deterrent and sanction, more so than prison or 
fines, but only when it is implemented quickly and for a period of 3–12 months (longer leads to 
non-compliance). Combining licence withdrawal with rehabilitation/treatment is more effective than 
licence withdrawal alone. Withdrawal of the licence of patients undergoing long-term treatment, 
including substitution treatment, should be based on an individual assessment of a patient’s fitness 
to drive overall, not simply on substance consumption.
Some driver rehabilitation schemes can reduce recidivism by an average of 45 %. Drivers with 
addiction or similar problems are unlikely to benefit from a rehabilitation programme and should be 
matched to more appropriate treatment. Rehabilitation options should vary according to the needs 
of different offenders.
emcdda.europa.eu
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Introduction
Across the current 27 Member States of the European Union (EU-27), 75 426 people lost their lives 
in road traffic accidents in just one year: 1991. Ten years later, by 2001, that annual toll had been 
reduced to 54 302. With this in mind, the EU’s Third Road Safety Action Programme 2003–10 set 
the ambitious objective of halving the number of road deaths in the EU by 2010, down to about 
27 000 in the EU-27. This target was not quite met, but the number of fatalities declined steadily 
over the period, reaching 31 029 in 2010 (1).
At the start of the 2003 Action Programme, it was estimated that about 25 % of fatalities on 
European roads were due to the influence of alcohol, but a lack of comparable studies meant that 
the proportion due to the effects of illicit drugs or psychoactive medicines was unknown. In the 
1990s, increased knowledge of the levels of illicit drug use among the general population was one 
of the factors that provoked interest in quantifying illicit drug use among drivers. However, the first 
attempts to estimate how many people were driving under the influence of psychoactive substances 
found that licit psychoactive medicines accounted for a higher proportion of drug-driving than illicit 
drugs. The issue is further complicated by the fact that some people take psychoactive medicines 
for recreational rather than therapeutic purposes.
Since the mid- to late 1990s, many studies have been carried out in an attempt to determine the level 
of drug-driving on European roads (2). However, these studies suffer from the use of different 
parameters and so the results are not comparable. A study in which drivers are tested at random in a 
small town on a Tuesday morning might find a prevalence of drug-driving of 0.5 %, whereas a study 
carried out on a Saturday night on a road leading to/from the nightclub district of a major city, and 
stopping only those vehicles being driven erratically, might find that 50 % of drivers test positive for 
drugs. There is similar scope for diversity in the definition of a ‘positive’ test. A study that considers the 
smallest trace of a substance in urine (in which metabolites can be detected for longer than blood) as 
‘positive’ will result in considerably higher prevalence rates than one that records only those drivers in 
whom drugs are found in blood, above a high value that has been calculated as ‘equivalent’ to 
impairment by alcohol. In a large study, matters are complicated by the fact that different toxicological 
laboratories have different equipment, and so one will report a sample as ‘positive’ when another 
would report the same sample as ‘negative’. Non-standardised studies of the situation preclude any 
meaningful evaluation of the effectiveness of the various responses and countermeasures.
For this reason, the DRUID (Driving Under the Influence of Drugs, Alcohol and Medicines) project 
was established, with the aim of estimating the size of the problem and examining the range of 
appropriate countermeasures.
As the DRUID project was being drawn up, the Working Group on Illegal Drugs and Driving, 
attached to the International Conference on Alcohol, Drugs and Traffic Safety, which meets 
approximately every 3 years (3), recommended that a consensus meeting of international drug-
(1) http://ec.europa.eu/transport/road_safety/pdf/observatory/historical_evol.pdf
(2) EMCDDA Insights 8: http://www.emcdda.europa.eu/publications/insights/driving
(3) http://www.icadts.org/
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driving researchers (toxicologists, epidemiologists, behavioural scientists, trauma specialists, police, 
etc.) should develop standards to serve as a basis for future research. Such guidelines could enable 
researchers to harmonise the design of future experiments and encourage collection of data on 
core standardised variables that would facilitate cross-study comparisons. The meeting was held in 
September 2006 in Talloires, France, and was attended by key experts who would be involved in 
the DRUID project, as well as experts from the United States and Australia (4). In this way, as the 
DRUID project launched, its protocols were already taking into account the various challenges 
involved in achieving international comparability.
The project ran for 5 years and involved 38 consortium partners from 17 Member States and 
Norway. The total cost was EUR 23 933 860, and the EC contribution was EUR 18 932 265. The 
50 full reports of this project (the project ‘deliverables’) are available on the project website and run 
to several thousand pages (see Annex 2). This thematic paper, therefore, aims to summarise the 
findings of one of the biggest and most important research projects ever carried out in the EU on 
drugs and driving.
(4) http://onlinelibrary.wiley.com/doi/10.1111/j.1360–0443.2008.02277.x/full
emcdda.europa.eu
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Part A: Understanding the problem
The DRUID project aimed to quantify the size of the drink- and drug-driving problem in Europe by 
estimating the number of individuals who would test positive for substance use in each participating 
country, and to determine whether the prevalence of drug-driving has any link with the prevalence 
of drug and medicine use in the population in general. Data obtained from various national studies, 
among others roadside surveys in 13 countries, were used to draw up a profile of the ‘typical’ 
substance-positive driver. Studies based on information from hospitals on drivers seriously injured or 
killed in road traffic accidents gave the percentage of these drivers tested positive for psychoactive 
substances. A comparison of information on the prevalence of substances in the injured drivers, the 
so-called ‘cases’, with information on the prevalence of substances in the driving population, the 
so-called ‘controls’, allowed estimation of the magnitude of the increased risk of being seriously 
injured or killed when driving while positive for various substances. This major epidemiological 
work was supplemented by results from experimental behavioural studies in which drivers were 
observed and tested under controlled conditions.
How common is drink- and drug-driving in Europe?
The prevalence of alcohol and other drug use in the driving population was assessed in 13 
European countries (Belgium, the Czech Republic, Denmark, Spain, Italy, Lithuania, Hungary, the 
Netherlands, Poland, Portugal, Finland, Sweden, Norway) based on the results of roadside surveys 
carried out between January 2007 and July 2009. According to the United Nations geoscheme, 
which divides Europe into regions (5) and limiting ‘Europe’ to the EU and Norway, these 13 
countries account for 89 % of the population of southern Europe and 63 % of the population of 
eastern Europe, but only 29 % of the population of northern Europe (as no survey took place in the 
United Kingdom) and 11 % of the population of western Europe (as no surveys took place in France 
or Germany). Therefore, care should be taken in extrapolating any of these outcomes to a pan-
European level. Detailed results can be seen in the table in Annex 1.
To ensure that results between countries were comparable, the DRUID project established 
common parameters for its roadside surveys. Drivers of passenger cars and vans were randomly 
selected using a stratified multistage sampling design. Regions were selected to be representative 
of the country with regard to substance use and traffic distribution. Within these regions, drivers 
in selected survey locations were stopped at random and asked to participate in the study (6). 
(5) http://unstats.un.org/unsd/methods/m49/m49regin.htm#europe
(6)  When participation in epidemiological studies is voluntary, as in this case, non-response and non-response bias 
are common problems. Non-response bias occurs when non-respondents differ from respondents with regard to 
drug and/or alcohol use. As the drug tests were mandatory only in Italy, researchers in other countries had to 
take into account non-response rates. If drivers under the influence of drugs and/or alcohol were more likely than 
non-users to refuse to participate, the results of the roadside surveys would underestimate the prevalence of 
psychoactive substance use. In this case–control study, underestimation of the prevalence among controls would 
result in overestimation of the risk associated with psychoactive substance use. In order to exclude a selective 
non-response bias, the response and non-response group were compared in terms of other variables to determine 
their degree of similarity.
emcdda.europa.eu
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The study population sample was stratified into eight time periods covering all the days of the 
week and all times of the day (7). In three countries (Belgium, Italy and the Netherlands) both 
blood and oral fluid were collected, in Lithuania only blood was collected, and in the 
remaining nine countries only oral fluid was collected. All countries used a StatSure Saliva 
(7)  The study population was not necessarily representative of the general driving population during the selected 
sampling periods because in many of the 13 countries sampling periods researchers were required to take into 
account the preferences of the police, who were needed to stop drivers in moving traffic. Weighting factors were 
applied to correct for this disproportion, based on the ratio by time period between the distribution of traffic and 
the distribution of the participants.
Figure 1.  Geographical distribution of DRUID roadside surveys, according to United Nations 
geoscheme
Southern Europe
Eastern Europe
Western Europe
Northern Europe
emcdda.europa.eu
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Sampler device for oral fluid collection, except the Netherlands, where oral fluid was collected 
in ordinary spit cups (8).
The substances under investigation were also standardised. A total of 23 substances, including 
ethanol (alcohol), were initially included in the ‘core substance list’. Three substances that most 
partners also included in their analyses were later added; the final core list of substances can be 
found in Annex 2. Some other frequently used psychoactive medicines, such as antidepressants, 
‘first-generation’ antihistamines, anti-epileptics and antipsychotics, were not included in the ‘core 
substance list’ by consensus, although some individual countries did choose to test for these 
substances. Some metabolites of the most common drugs were also included on the list, either as 
the original drug cannot be detected in the body (e.g. 6-AM as an indicator of heroin use) or as 
they had already been established as core analytes in other driver surveys (e.g. THC-COOH 
(carboxy-THC) from THC and benzoylecgonine from cocaine).
All samples were confirmation analysed by toxicological laboratories. In order to achieve 
agreement on what would be recorded as a ‘positive’ result, an analytical cut-off (limit) was set for 
each substance. This cut-off was initially based on the lowest detectable quantity, the ‘limit of 
quantification’ (LOQ), but this is different in each toxicological laboratory owing to the use of 
different instruments and procedures. To ensure that results were comparable, analytical cut-offs 
were chosen that could be measured by all laboratories for each of the core substances.
However, some substances are found at much higher concentrations in oral fluid than in blood, 
whereas in the case of other compounds the opposite is true. For example, one of the main 
metabolites of cannabis, THC-COOH, is not detectable in oral fluid when it is detectable in blood, 
as its concentrations in oral fluid are extremely low (pg/ml); thus an oral fluid test result would be 
registered as negative, when a blood test of the same driver would be registered as positive. For 
this reason in particular, THC-COOH was excluded from the final list of recommended test 
substances. For other substances for which the difference was not so great, studies were conducted 
to calculate equivalent cut-off concentrations (above the analytical cut-offs) for blood samples and 
oral fluid samples taken with the StatSure saliva sampler. The agreed equivalents would then be 
used to categorise a sample as positive or negative. Such equivalent concentrations have not 
previously been calculated between whole blood and oral fluid, and thus they constituted an 
important outcome of this study, solving the problem of two different sample types being collected 
in roadside surveys. When both an oral fluid and a blood sample were taken from a driver, the 
result of the blood analysis was given preference.
In total, over 50 000 car and van drivers in the 13 participating countries provided an oral fluid 
sample, a blood sample or both. This permitted estimation of the current prevalence of alcohol and 
other drugs in the driving population across a large part of Europe.
Alcohol was the psychoactive substance most frequently detected in the general driving population. 
The results were broken down into those above the agreed analytical cut-off in blood, those above 
(8)  In popular discussion, the word ‘saliva’ is often used to mean ‘oral fluid’. Strictly speaking, ‘saliva’ is the fluid 
collected from a specific salivary gland and is free from other materials. ‘Oral fluid’ is the saliva from the various 
salivary glands, mixed with other constituents present in the mouth. https://www.ncjrs.gov/pdffiles1/nij/
grants/203569.pdf
emcdda.europa.eu
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the common legal blood alcohol content (BAC) of 0.5 g/l, and those above the common legal 
definition of severe intoxication of 1.2 g/l BAC. The results can be summarised as follows:
Blood alcohol content Weighted mean across 12 countries (1) Range
≥ 0.1 g/l 3.5 % 0.15 – 8.59 %
≥ 0.5 g/l 1.5 % 0.07 – 5.23 %
≥ 1.2 g/l 0.4 % 0.01 – 1.47 %
(1)  No alcohol results were available for Sweden. Alcohol-positive drivers (over 0.2 g/l) were dealt with by the police and so did not 
take part in the survey.
The prevalence of illicit drugs in the general driving population, though varying widely between the 
different countries, was much lower than that of alcohol:
Illicit drug groups Weighted mean across 13 countries Range
All drugs 1.9 % 0.2 – 8.2 %
THC 1.32 % 0.0 – 5.99 %
Cocaine 0.42 % 0.0 – 1.45 %
Amphetamines 0.08 % 0.0 – 0.38 %
Illicit opioids 0.07 % 0.0 – 0.3 %
THC was the illicit drug most frequently detected in drivers, followed by cocaine. Amphetamines 
and illicit opioids were less frequently detected.
The prevalence of some frequently used psychoactive medicines (benzodiazepines, medicinal 
opioids, and ‘z-drugs’ such as zopiclone and zolpidem) in the driving population across Europe 
was, on average, lower than the prevalence of alcohol and illicit drugs:
Medicine groups Weighted mean across 13 countries Range
All medicines 1.4 % 0.17 – 2.99 %
Benzodiazepines 0.9 % 0.14 – 2.73 %
Medicinal opioids 0.35 % 0.00 – 0.79 %
Z-drugs 0.09 % 0.00 – 0.69 %
Benzodiazepines were the most often detected medicine in drivers, with medicinal opioids and 
z-drugs less common. Once again, prevalence varied greatly between the different countries.
Combinations of alcohol, illicit drugs and medicines were not included in the above figures, but 
recorded separately, as follows:
Combinations Weighted mean across 13 countries Range
Alcohol with drugs and/or medicines 0.37 % 0.00 – 1.14 %
Combinations of drugs and/or medicines 0.39 % 0.00 – 1.22 % 
emcdda.europa.eu
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Figure 2.  Distribution of alcohol, illicit drugs and medicines found in car drivers 
in 13 European countries
Not available
Below European average
European average
Above European average
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In summary, the highest prevalence was found for alcohol, more frequently in drivers in the southern 
countries of Europe. Regarding medicines and illicit drugs, there was a tendency towards greater 
use of medicines by drivers in the northern countries and greater use of illicit drugs by drivers in the 
southern countries.
The use of alcohol, illicit drugs, and medicines was relatively low in most of the eastern countries 
compared with the other European regions whereas drug use by drivers in the two western 
European countries was more or less on a parallel with the European average.
emcdda.europa.eu
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Combined use of alcohol and drugs and multiple drug/medicine use were more common in drivers 
in the southern region. After alcohol, the substances most commonly used in combinations were 
THC, cocaine and benzodiazepines.
A study to determine national rates of drug and medicine consumption in the general population 
found that, across Europe, there is a tendency for the consumption in the driving population to 
reflect the consumption in the whole population, i.e. the prevalence of medicines is relatively higher 
in the Nordic countries and the prevalence of illicit drugs use is comparatively higher in the 
southern countries of Europe. However, it would not be correct to assume that, just because there is 
a high rate of substance use among the general population of a country, a similarly high rate 
would be found in the driving population.
The details of the research and findings can be found in the deliverables from Work Package 2 — 
see Annex 3.
How often are psychoactive substances found in drivers seriously 
injured or killed in road traffic accidents?
A cross-sectional survey was conducted to determine the prevalence of alcohol and other drugs in 
drivers seriously injured (sampled between October 2007 and May 2010) or killed (sampled 
between January 2006 and December 2009) in road traffic accidents in nine European countries. 
Studies of hospitalised, seriously injured, car drivers were conducted in six countries (Belgium, 
Denmark, Italy, Lithuania, the Netherlands, Finland); studies of car drivers killed in accidents took 
place in four countries (Portugal, Finland, Sweden, Norway). Once again, a uniform study design 
was developed for all participating countries. Obligatory inclusion criteria were as follows: driver 
of a motorised vehicle; injured in an accident on a public road or in the direct vicinity of a public 
road; primary admission to the hospital only (no referrals), for trauma-related reasons, with a time 
interval between the accident and sampling of less than 3 hours; and a MAIS (Maximum 
Abbreviated Injury Scale) score of 2 or higher. For those counted as killed drivers, the time between 
accident and death was a maximum of 24 hours. Each country could decide upon additional 
national criteria. Finally, the study considered the relatively similar subpopulations of passenger car 
and van drivers, and so the results are compiled from 2 492 drivers seriously injured and 1 118 
drivers killed in road traffic accidents.
Alcohol was the substance most frequently detected in drivers seriously injured or killed:
Range (seriously injured) Range (killed)
Alcohol 14.1 – 30.2 % 15.6 – 38.9 %
The highest percentage of seriously injured drivers who tested positive for alcohol was found in 
Belgium, whereas the highest percentage of drivers killed in accidents who tested positive for 
alcohol was found in Portugal. Overall, 24.4 % of the injured driver population and 31.7 % of the 
killed driver population tested positive for alcohol. Of those injured and killed drivers who tested 
positive for alcohol, 70 % were severely intoxicated, with BAC ≥ 1.2 g/l.
emcdda.europa.eu
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The use of illicit drugs among drivers seriously injured or killed varied between the countries. The 
use of illicit drugs alone was not frequently detected among drivers injured or killed in Europe, as 
visible in the following table; in the majority of cases, illicit drugs were found in combination with 
other psychoactive substances, mainly alcohol. THC (and/or THC-COOH) seemed to be one of the 
most prevalent illicit drugs, followed by cocaine and amphetamines:
Illicit drug groups Range (seriously injured) Range (killed)
THC (and/or THC-COOH) 0.5 – 2.2 % 0.0 – 1.8 %
Cocaine (and/or benzoylecgonine) 0.0 – 1.3 % 0.0 – 0.0 %
Amphetamines 0.0 – 1.1 % 0.0 – 2.1 %
Illicit opiods 0.0 – 0.7 % 0.0 – 0.0 %
The highest percentage of seriously injured drivers found to be cannabis positive was in Belgium 
and the lowest in Lithuania. The highest percentage of drivers killed in accidents who tested positive 
for cannabis was in Norway and the lowest was in Finland. Amphetamine use appeared to be 
more common in northern Europe. No drivers killed in accidents in Portugal tested positive for 
amphetamines. Cocaine use seemed to be more common in southern Europe than elsewhere. In 
Finland no drivers seriously injured or killed tested positive for cocaine. No illicit opioids were 
found in the drivers killed in accidents.
Regarding medicines, the findings among drivers injured and killed were as follows:
Medicine groups Range (seriously injured) Range (killed)
Benzodiazepines 0.0 – 2.3 % 0.0 – 5.2 %
Medicinal opioids 0.0 – 5.7 % 0.6 – 1.5 %
Z-drugs 0.0 – 2.1 % 0.0 – 2.8 %
Among injured drivers, the most frequently found substances after alcohol and THC were 
benzodiazepines, whereas, among drivers killed in accidents, benzodiazepines were second only 
to alcohol, followed by amphetamines. Benzodiazepine use appears to be more common in 
northern Europe, in drivers both seriously injured and killed, with the highest proportion of positive 
tests in both categories found in Finland. In the Netherlands no seriously injured drivers tested 
positive for benzodiazepines. Z-drug use was found only in northern Europe; no positive findings 
were recorded in Italy, Lithuania or Portugal. Medicinal opioids were found in all countries, with the 
greatest use in seriously injured drivers in Lithuania and the lowest use in the Netherlands. In 
Sweden, the percentage of drivers killed in accidents who tested positive for medicinal opioids was 
twice that found in Portugal, Finland or Norway.
Regarding combinations of substances, the findings among drivers injured and killed were as follows:
Combinations Range (seriously injured) Range (killed)
Alcohol with drugs and/or medicines 2.3 – 13.2 % 4.3 – 7.9 %
Combinations of drugs and/or medicines 0.5 – 4.3 % 0.4 – 7.3 %
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Figure 3.  Distribution of psychoactive substances found in seriously injured or killed drivers
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Among drivers seriously injured or killed, the most commonly consumed substance was alcohol 
alone, followed, in all countries except Lithuania, by alcohol combined with another substance. 
Combined drug/medicine users were either the third (in Belgium, Denmark, Italy and Finland) or 
fourth (in Lithuania and the Netherlands) most common group. Thus, the biggest problem with illicit 
drugs is their consumption in combination with other psychoactive substances, especially alcohol. 
Although the rates of combined consumption were not high, the risk of injury is clearly increased in 
these cases.
The details of the research and findings can be found in the deliverables from Work Package 2 — 
see Annex 3.
Who is the ‘average person’ found driving after taking psychoactive 
substances?
Data collected during the roadside surveys allowed a description to be drawn of the ‘average 
driver’ testing positive for the different substance groups. These included younger drivers (in the age 
range 18–34 years), middle-aged drivers (35–49 years) and older drivers (≥ 50 years).
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Characteristics of drivers testing positive for alcohol
Among the general driving population, alcohol was most often detected among male drivers over 35, 
BAC values were relatively low (9) and most positive tests were recorded on weekday nights and at 
weekends. Among drivers involved in accidents, alcohol was most often detected among younger 
male drivers (25–34 years) and the mean BAC level was high; most were severely intoxicated.
Interviews with problem drink-drivers in Hungary and Sweden found that drivers do not believe that 
alcohol impairs their performance. Problem alcohol users who drank and drove stated that losing 
their licence or even imprisonment would not have helped them to stop reoffending; instead, they 
claimed that a subsequent treatment programme had helped them by giving them a greater insight 
into their problems.
Characteristics of drivers testing positive for illicit drugs
Among the general driving population, illicit drugs were mainly detected among young male 
drivers, and at all times of the day but mostly at the weekends. However, the most frequent time 
period differed according to country, and the user profile differed according to substance. 
Cannabis and cocaine were most prevalent among young male drivers (in the age ranges 18–34 
years and 25–34 years, respectively). Amphetamines were most prevalent among young drivers 
(18–34 years), but the gender distribution differed according to country. Illicit opioids were most 
prevalent among male middle-aged drivers (35–49 years). The highest prevalence of the combined 
use of alcohol and drugs (illicit drugs and/or psychoactive medicine) was generally found in young 
male drivers (18–34 years) during night-time hours. Multiple drug use (illicit drugs and/or 
psychoactive medicines) was generally most common in males, and in middle-aged drivers (under 
50), although age groups and time periods varied considerably by country.
The studies of drivers seriously injured or killed found that illicit drugs were most prevalent in young 
and middle-aged drivers (under 50 years), usually male, and the majority of drugs appeared to be 
used in combination with other psychoactive substances (mainly alcohol).
Interviews with Swedish drivers who were problem drug users revealed that they did not believe that they 
would be stopped by the police, or that alcohol or drugs would impair their driving, and therefore they 
did not perceive any real risks in driving. A survey of 195 German drug-using drivers found that intensive 
users did not feel impaired, even though they were, and were more likely to drive under the influence, 
whereas moderate substance users could realistically judge their level of intoxication and took a more 
responsible approach to drugs and driving, choosing to drive less often or not at all after taking drugs.
Characteristics of drivers testing positive for psychoactive medicines
In the general driving population, psychoactive medicines, both benzodiazepines and medicinal 
opioids, were mainly detected among middle-aged and older female drivers (≥ 35 years) during 
daytime hours. However, the studies of the drivers seriously injured or killed found these substances 
(9)  Except in Lithuania, where 38 % of drivers testing positive for alcohol alone had a BAC of over 1.2 g/l.
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to be more prevalent in male drivers in the same age range, and the majority were detected in 
combination with other psychoactive substances (alcohol or drugs).
The details of the research and findings can be found in the deliverables from Work Package 2 — 
see Annex 3.
What do experiments show regarding the effects that different 
substances have on driving ability?
In addition to considering large-scale studies of the numbers of drivers seriously injured or killed, 
the effects of the substances were also gauged using both meta-analyses of previously published 
experimental studies and 13 driving tests on public roads or using driving simulators involving 
different substances or their combinations and different participant groups (patients or drug users 
as appropriate).
Meta-analyses of experimental studies
The meta-analysis of experimental studies of alcohol considered 450 published papers in which 
5 300 findings concerning alcohol effects were included. These results allowed calculation of an 
impairment function that could then be used to determine the concentration of psychoactive 
substances causing the same level of impairment as certain BAC levels.
The meta-analysis of experimental studies of medicines and illicit drugs considered 605 
publications. This meta-analysis provided information about the impact of antipsychotics, 
anxiolytics, hypnotics, sedatives, antidepressants, antihistamines and major illicit drugs on driving 
and skills related to driving. It found that a few anxiolytics, antidepressants and sedatives and one 
antipsychotic caused considerable impairment at certain doses, as did oral administration of THC 
(e.g. consumption in cake, tea). Neither antihistamines nor illicit drugs (even THC from smoking 
cannabis) caused comparable impairment. A significant finding from the meta-analysis was that a 
serum concentration of 3.8 ng/ml THC (≈ 2 ng/ml in whole blood) was shown to be as impairing 
as 0.5 g/l BAC. In the experimental studies analysed, no negative influence on fitness for driving 
was found for the illicit stimulants d-amphetamine, MDMA and cocaine; in general, there were 
more findings of improved performance than of impaired performance. However, some case 
reports and non-experimental publications examining cocaine revealed negative effects.
The maximal impairment of a substance is an important parameter in estimating the danger 
associated with use of that substance; however, maximum impairment may be of short or long 
duration. Therefore, for each substance that had been the subject of sufficient experimental studies, 
the project used the impairment function to construct an impairment curve, showing the degree of 
impairment over time. Once the curve was constructed, the ‘area under the curve’ was calculated to 
capture both the level of impairment and the duration. To exclude minor effects, a line was drawn 
to represent impairment equivalent to 0.3 g/l BAC. The final measure of the danger of a substance, 
the ‘degree of impairment’, indicates the area between the approximation curve and the minor 
impairment line, thus capturing in a single parameter both the intensity (magnitude of impaired 
effects) and duration of impairment (see Figure 4).
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Table 1.  Degree of impairment sorted in ascending order within the different  
substance classes
Class Substance/Dose [mg] Degree of impairment
Anxiolytics
Buspirone (10)
Buspirone (20)
Clobazam (10)
Clobazam (20)
Meprobamate (400)
Meprobamate (800)
Diazepam (5)
Diazepam (10)
Lorazepam (1)
Oxazepam (15)
Diazepam (15)
Oxazepam (30)
Diazepam (20)
Alprazolam (1)
Lorazepam (2)
Lorazepam (2.5)
  0
  0
  0
  0
  0
  0
 17
 57
 64
104
112
170
171
369
418
571
Hypnotics and sedatives
Temazepam (10)
Zolpidem (5)
Lormetazepam (1)
Temazepam (20)
Zaleplon (10)
Triazolam (0.25)
Flunitrazepam (1)
Zolpidem (10)
Zolpidem (20)
Zopiclone (7.5)
Triazolam (0.5)
Flunitrazepam (2)
  0
  0
 22
 40
 40
 89
115
119
214
240
247
461
Antipsychotics
Sulpiride (400)
Haloperidol (3)
Promethazine (27)
  0
 93
491
Antidepressants
Fluoxetine (60)
Paroxetine (30)
Imipramine (75)
Trazodone (100)
Mianserin (10)
Amitriptyline (25)
Amitriptyline (50)
  0
  0
 32
 87
185
327
380
Antihistamines
Fexofenadine
Loratadine (10)
Terfenadine (60)
Diphenhydramine (25)
Diphenhydramine (50)
  0
  0
  0
 54
 92
Illicit drugs
d-amphetamine (24.75)
d-amphetamine (4.25)
THC oral admin. (8.25)
THC smoking (5)
THC oral admin. (13.5)
THC smoking (13.5)
THC oral admin. (24.5)
  0
  0
  0
 66
 68
 70
215
Note: For missing substance/dose combinations no degree of impairment exists.
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Figure 4.  Diazepam 20 mg, time-dependent impairment (29 studies, 276 effects)
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In the case of narcoanalgetics, hallucinogens, and opioids used mainly in substitution treatment 
for opioid addicts (morphine, methadone and buprenorphine), the number of published studies 
was too low to carry out a meta-analysis, so their effects on drivers were summarised in a 
review of the literature. Finally, the project’s expert workshop on heroin substitutes concluded 
that no distinction should be drawn between patients undergoing substitution treatment and 
patients receiving other medicinal treatments, but addiction to other impairing substances is 
clearly an exclusion criterion for driving. Patients are not fit to drive during the adjustment 
phase, but this is generally short (around 3 weeks). Periods of large dose changes require 
attention but gradual detoxification does not. The three substitution substances and the amount 
of the daily dosage in milligrams are no criteria for the fitness to drive, as long as they are 
adequate for each client. With all this in mind, decisions should be made on a case-by-case 
basis.
Driving tests
These were standardised, and comprised tests of road tracking (‘standard deviation of the lateral 
position’, or weaving/swerving), car following and risk-taking (overtaking, jumping traffic lights), as 
well as laboratory tests that included attention, cognitive and reaction tests. All studies on the 
impact of illicit drugs adopted placebo-controlled, double-blind, within-subjects study designs. All 
studies employed representative subject samples, i.e. recreational users of MDMA and 
dexamphetamine, and patients of the prescribed medicines being tested, who were screened for 
presence of alcohol and other drugs before each test. Most of the studies employed crossover 
designs to provide maximal statistical power with relatively small sample sizes. Most were 
conducted in real traffic although some utilised advanced driving simulators; one, for legal reasons, 
was carried out on a closed driving circuit.
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None of the studies investigating the effects of stimulants on driving (MDMA and dexamphetamine) 
found that drug consumption alone resulted in increased impairment or risk-taking. Increased 
risk-taking behaviour was observed only in the case of additional alcohol consumption. In general, 
low doses of stimulant drugs produce neutral or even stimulating effects on a range of psychomotor 
functions. However, some studies found that stimulants may also have detrimental effects on specific 
cognitive functions and increase risk-taking behaviours. Considering the likely drug use setting, the 
stimulant effects of MDMA and amphetamine were not sufficient to overcome or compensate for 
driving impairments resulting from concomitant alcohol use or a night’s sleep deprivation; in fact, 
MDMA in combination with alcohol (or sleep deprivation) impaired driving performance. 
Moreover, users of stimulant drugs were not aware of post-acute fatigue effects (the ‘comedown’). 
One night of sleep deprivation alone caused impairments comparable to those observed under the 
influence of 0.8 g/l BAC.
With regard to medicines, zopiclone (7.5 mg) and alprazolam (0.5 mg) produced significant 
driving impairment in patients as well as in healthy control subjects, although chronic users 
experienced no subjective feelings of reduced alertness or drowsiness. Thus, insomniacs and 
anxiety patients may believe that they can drive safely while taking these drugs, even though 
their performance is in fact impaired. However, the driving performance of patients suffering 
from insomnia who had been prescribed short-acting hypnotics or low doses of hypnotics 
generally did not differ from that of normal sleepers. In contrast, sleep apnoea was strongly 
correlated with driving impairment. In the case of analgesics, it was found that the impairment 
potential of codeine/paracetamol combinations increases with age. Dronabinol (Marinol®), 
synthetic THC used for the treatment of chronic pain, impaired driving performance in 
occasional cannabis users to the same level as 0.5 g/l BAC, whilst the effect was less in daily 
cannabis users. The driving performance of patients suffering from chronic pain and undergoing 
long-term treatment with opioid analgesics was generally similar to that of healthy control 
subjects.
The details of the research and findings can be found in the deliverables from Work Package 1 — 
see Annex 3.
What is the risk of being seriously injured, dying or of killing 
someone after taking drugs and driving?
In statistical terms, the relative risk, also known as the risk ratio, signifies the risk of an event 
(injury or death by crashing a car) relative to exposure (consuming a psychoactive substance). 
The correct way of calculating risk is to follow a large cohort of drivers for some time, observe 
how many consume psychoactive substances and then observe how many crash. Obtaining 
results on a large scale in this way would be prohibitively expensive, so the practical way of 
calculating the risk of such a rare event is to carry out a case–control study and use the results 
to calculate odds ratios, which in this case approximate to relative risk. A risk ratio of 3, for 
example, means that a substance-positive driver is three times more likely to crash than a sober 
driver.
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In the DRUID project, to calculate the relative risk of having a serious accident when positive for a 
substance, four numbers were required:
•   the number of cases (here, obtained from hospital studies of drivers seriously injured/killed) 
positive for a given substance group;
•   the number of controls (here, drivers in the roadside surveys on roads close to those hospitals) 
positive for a given substance group;
•   the number of cases (here, obtained from hospital studies of drivers seriously injured/killed) 
negative for any substance; and
•   the number of controls (here, drivers in the roadside surveys on roads close to those hospitals) 
negative for any substance.
Once these numbers had been collected, the relative risk of a driver being seriously injured in an 
accident was approximated to the odds ratio between the odds of a driver being seriously injured in 
an accident while positive for a given substance and the odds of being seriously injured while 
negative. The relative risk of a driver being killed in an accident was estimated in the same way. The 
odds ratios for the different substance groups were calculated using logistic regression and adjusted 
for age and gender, as an approximation for the relative risk. In both cases, samples were considered 
positive if the concentration was at or above the equivalent cut-off in either blood or oral fluid.
Data from the case study population consisted of samples from the hospital studies of seriously 
injured drivers in six countries (Belgium, Denmark, Italy, Lithuania, the Netherlands, Finland) and 
those of killed drivers from four countries (Portugal, Finland, Sweden, Norway). In total, 2 490 
seriously injured drivers and 1 112 killed drivers were included. Data from the control population 
came from the roadside surveys in the same countries; in total, 15 832 drivers participated in the 
control sample of the seriously injured drivers and 21 917 drivers participated in the control 
samples of killed drivers; data were weighted for the national distribution of traffic in each of eight 
time periods of the week. The relative risk estimates were adjusted for age and gender.
Despite the scale of the project, the number of subjects, both cases and controls, testing positive for 
each substance was very low, with some countries finding none. Although this is fortunate from a 
road safety point of view, it results in imprecise odds ratio estimates with broad confidence 
intervals. There are also considerable variations among countries’ results that are not easy to 
explain. The data were pooled to give more reliable ratios, with smaller confidence intervals, and 
are presented as four general levels of increased risk of being seriously injured or killed in a traffic 
accident. Nevertheless, the overall results for illicit drugs in particular, because of the very low 
number of positives (cocaine and illicit opioids) or wide variability between countries (cannabis and 
amphetamines), should be treated with caution. The rarity of positive toxicological results also 
meant that the small numbers of drivers with (very) low and (very) high substance concentrations 
were pooled. It was not possible to determine the difference between concentrations when 
calculating the risk for any substance other than alcohol. Although benzoylecgonine is an inactive 
metabolite of cocaine, the risk of being seriously injured or killed while positive for 
benzoylecgonine was calculated in order to determine if the risk of road traffic accidents is 
increased when only metabolites are present, i.e. after recent drug use.
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Table 2.  Project findings — the relative risk level of being seriously injured or killed in an 
accident while positive for various substance groups
Risk level Relative risk Substance group
Slightly increased risk  1–3
0.1 g/l ≤ alcohol in blood < 0.5 g/l
Cannabis
Medium increased risk  2–10
0.5 g/l ≤ alcohol in blood < 0.8 g/l
Benzoylecgonine
Cocaine
Illicit opioids
Benzodiazepines and z-drugs
Medicinal opioids
Highly increased risk  5–30
0.8 g/l ≤ alcohol in blood < 1.2 g/l
Amphetamines
Multiple drugs
Extremely increased risk 20–200
Alcohol in blood ≥ 1.2 g/l
Alcohol in combination with drugs
Notes: Cannabis and amphetamines: owing to very different single-country estimates, the risk estimates must be treated with caution.
Benzoylecgonine, cocaine and illicit opioids: owing to few positive cases and controls, the risk estimates must be treated with caution.
This elevated risk for amphetamines and other stimulants is very different from the findings of the 
experimental studies in the DRUID project. When amphetamine was found in drivers injured or 
killed in road traffic accidents, the median concentrations were very high compared with the 
concentrations of subjects in the experiments; these may have detrimental effects on self-perception, 
critical judgement and risk-taking, and while the stimulating effects are wearing off the driver may 
suffer fatigue, anxiety and irritability. It is also likely that drivers who choose to drive when positive 
for (large concentrations of) amphetamines are more prone to taking risks than the average road 
user. The risk associated with benzoylecgonine, which is not an active agent, might be caused by 
sleep deprivation after consumption of cocaine.
Using a different method, a pharmacoepidemiological study carried out in the Netherlands 
linked pharmacy, traffic accident and hospital databases to calculate the relative risk of a patient 
being involved in an accident while using medication. The case population was defined as adults 
involved in a traffic accident between 2000 and 2007 and who were driving and received 
medical assistance. The control population was defined as adults holding a driving licence who 
were not involved in a traffic accident during the study period. In total, 3 963 cases and 18 828 
controls were selected for the case–control analysis. Calculations showed an increased accident 
risk for drivers exposed to at least one psychotropic medication (relative risk 1.3), drivers 
undergoing treatment with a combination of medicines (relative risk 1.5) and those taking 
modern antidepressants (relative risk 1.7). The study identified high-risk groups such as new 
users, intermediate and long half-life benzodiazepine users, female users and young/middle-
aged users.
Responsibility studies involve deciding whether or not the driver was responsible for the accident, 
rather than simply being involved in it. This can be assessed in two ways. In the first, investigation 
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teams comprising traffic safety and car inspection engineers, without knowing of any impairment of 
the driver, study each accident to determine responsibility. In the second, researchers compute a 
responsibility score, based on information from eight groups of characteristics: road conditions; 
traffic conditions; vehicle conditions; crash type; complexity of the driving task; complexity of traffic 
regulation; tiredness of the driver; and witnesses’ comments. The DRUID project used an adaptation 
of the ‘responsibility score’ calculation to estimate the risk of being responsible for a fatal accident 
while positive for a psychoactive substance.
Relative risk estimates for the responsibility of drivers killed while positive for alcohol and other 
drugs were based on data from Germany, Lithuania, Hungary and Slovakia. In total, 483 drivers 
were included in the study. However, largely because of the low number of controls, the analysis 
could not detect an effect of individual substances on the risk of being responsible for a fatal 
accident, except for BAC ≥ 1.2 g/l. Nevertheless, the DRUID project also benefited from the 
dataset of an earlier responsibility study in France, to which the new DRUID cut-offs were applied. 
Blood samples were taken from 7 455 car drivers involved in fatal accidents in the period October 
2001 to September 2003, whether they were killed, injured or unharmed; therefore, the group was 
different from the killed drivers above, and so the two datasets could not be combined. The 
reference group was car drivers with a BAC < 0.1 g/l. Again, the relative risk estimates were 
approximated to odds ratios. This analysis found that the risk of being responsible for a fatal crash 
was five to eight times higher for a driver under the influence of alcohol (BAC ≥ 0.1 g/l) than for a 
sober driver; the risk of severely intoxicated drivers (BAC ≥ 1.2 g/l) being responsible for a fatal 
crash was 15–21 times higher than that for sober drivers. Drivers involved in fatal accidents and 
positive for cannabis (≥ 1 ng/ml) had a risk about twice that of drivers not positive for cannabis. 
Combined use of alcohol and cannabis multiplies the risk of causing a fatal accident. In the case of 
amphetamine, cocaine and illicit opioids, odds ratios of responsibility adjusted for age and gender 
were not significantly different from 1, meaning that the risk of responsibility for positive drivers was 
not significantly different from that of sober drivers. This may have been a result of the small 
number of drivers in the sample that tested positive for those substances.
The details of the research and findings can be found in the deliverables from Work Package 2 — 
see Annex 3.
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Part B: Examining the possible responses
In addition to understanding the size of the problem, policymakers need to know how to respond to 
it efficiently and effectively. This is particularly complex, given the difference in legal status of the 
substances involved and the wide variety of social attitudes towards them. The problem can be 
addressed in various ways. Prevention programmes targeting illicit drugs usually consist of 
information campaigns and are frequently aimed at young people in an attempt to dissuade them 
from taking drugs and driving. However, prevention programmes aimed at users of psychoactive 
medicines may be broader in scope, addressing physicians and pharmacists to encourage them to 
review their prescribing and dispensing practices, as well as addressing patients who may be 
taking those medicines and are unaware of their effects on driving skills. Laws may act as a 
deterrent, punishing impaired driving or simply driving with any of these substances in the body, 
and these may be enforced by police using clinical tests or analytical roadside screening devices. 
Rehabilitation of offenders aims to stop reoffending in the future. All these responses require 
financial and human resources, which are under increasing pressure in Europe at present, so it is 
essential that policymakers can identify the most efficient and effective responses and avoid those 
that may seem instinctive or attractive but, when evaluated objectively, do not give value for money.
How to assess the driver’s fitness to hold a licence?
Driver licensing across Europe is regulated by Council Directive 91/439/EEC of 29 July 1991 on 
driving licences. Annex III of that Directive states that ‘Driving licences shall not be issued to or 
renewed for applicants or drivers who are dependent on psychotropic substances or who are not 
dependent on such substances but regularly abuse them’. Addressing legally prescribed medicines, 
it also states that ‘Driving licences shall not be issued to, or renewed for, applicants or drivers who 
regularly use psychotropic substances, in whatever form, which can hamper the ability to drive 
safely where the quantities absorbed are such as to have an adverse effect on driving. This shall 
apply to all other medicinal products or combinations of medicinal products which affect the ability 
to drive.’ As a Directive, the obligations of this law must be implemented in all countries in the EU; 
individual countries should not deviate from it. With this in mind, one of the aims of the project was 
to consider whether, 20 years later, the wording of the Directive is still appropriate in the light of 
developments in road safety and public health policy.
Little is known about how the Directive is implemented in the different countries. Therefore, a 
questionnaire survey of driver licensing authorities and experts was conducted in 29 European 
countries (all EU Member States and Norway and Switzerland) requesting information on 
guidelines for physicians on prescribing medicines with impact an on driving performance and on 
assessing fitness to drive. In addition, existing guidelines for pharmacists on advising patients while 
dispensing those medicines were considered. The survey found that the regulations in the different 
countries dealing with the procedures for assessing fitness to drive are mainly in line with the 
European Council Directive. However, practical implementations and the assignment of 
responsibilities differ from country to country. Based on these findings, it was very difficult to derive 
a ‘best practice’ for implementation. Nevertheless, the project made a number of recommendations 
to be considered when redrafting the Directive, including clearer distinction between (illicit) drugs 
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and medicines and updating terms such as ‘abuse’, ‘dependence’ and ‘regular use’, which now 
have changed or unclear meanings. Importantly for users of psychoactive medicines, it 
recommended that the final decision on fitness to drive should take into account not only the 
substance involved but also the underlying reason for taking medicines and comorbidity factors.
The details of the research and findings can be found in the deliverables from Work Package 7 — 
see Annex 3.
Which public information campaigns are effective?
A review of existing information campaigns on the risks of driving after taking drugs or medicines 
found a total of 75 information campaigns from 13 different countries, including the United States, 
Canada and Australia. The majority of those (37) concerned driving under the influence of drugs, 
while 22 gave information about medicines alone, and 16 addressed both illicit drugs and 
medicines. Thirty were designed specifically for young people, 23 for the general public, 16 for 
physicians and/or pharmacists, nine for teachers, seven for patients using particular medicines, four 
for parents and five for another target population (e.g. drug users, heavy vehicle operators, 
employers). Some campaigns were designed for more than one target population. Most of the 
information campaigns identified were conducted through the mass media. Brochures (3–19 pages) 
were the medium used most frequently, followed by posters, print press, websites, booklets, 
television and radio commercials, leaflets, tutorials and other media. Most campaigns were run by 
governmental organisations or road safety organisations.
Information on the impact of the campaign was found for only 7 of the 75 campaigns, and all 
these evaluations documented a positive outcome. However, some simply measured the impact in 
the form of awareness of the campaign (minimum effect), rather than the impact on driver attitude 
and behaviour (maximum effect). The effects were mostly assessed through interviews; only one 
campaign gathered objective data concerning drug-related road deaths. As only a few evaluations 
were found, and these campaigns and their evaluations were performed in different ways, it is not 
possible to draw conclusions concerning the association between the design of the campaigns and 
their effectiveness. Therefore, the project was unable to make any recommendations as to the 
design of an effective information campaign. Nevertheless, the study noted the conclusions of 
broader research on similar themes, such as the EU’s GADGET project, in which a large 
international sample of evaluated campaigns was collected, and the effect of the campaigns on 
accidents was evaluated as a function of certain variables (10). Future campaigns concerning 
driving under the influence of drugs and/or medicines should follow a common evaluation, in order 
to develop more effective campaigns. Detailed guidance for evaluating road safety campaigns has 
been drawn up by the EU’s CAST project (11).
The details of the research and findings can be found in the deliverables from Work Package 7 — 
see Annex 3.
(10) http://www.kfv.at/index.php?id=829&contUid=2141
(11) http://www.cast-eu.org/
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How could psychoactive medicines be better classified, 
labelled and dispensed?
The DRUID project reviewed existing national systems that classified medicines in terms of their 
effect on driving performance. In total, 16 systems were found, with varying numbers and 
descriptions of categories. A classification and labelling system was developed (Table 3) that 
classified medicines into four categories. The first step in harmonisation across Europe was 
achieved with the adoption of the Guidelines for the Summary of Product Characteristics in 
September 2009 (valid from May 2010), which specify four categories — (a) no or negligible 
influence; (b) minor influence; (c) moderate influence; and (d) major influence on driving fitness — 
with some important guidance in special circumstances.
Table 3. DRUID categorisation system for medicines and driving
Information for physicians and pharmacists Warning for patients (with 
warning symbols and standard 
descriptions per country)
Description of categories 
with levels of impairment (1)
Information on how to advise patients
Category 0
Presumed to be safe or 
unlikely to have an effect on 
fitness to drive
Confirm that the medicine will be safe for 
driving, provided that combinations with 
alcohol and other psychotropic medicines are 
excluded 
[No warning needed]
Category 1
Likely to have minor adverse 
effects on fitness to drive
Inform the patient that impairing side-effects 
may occur, especially during the first days 
that may have a negative influence on his or 
her driving ability. Advise the patient not to 
drive if these side-effects occur
Warning level 1
Do not drive without having read 
the relevant section on driving 
impairment in the package insert
Category 2
Likely to have a moderate 
adverse effect on fitness to 
drive
Inform the patient about the possible 
impairing side-effects and the negative 
influence on his or her driving ability. Advise 
the patient not to drive during the first few 
days of the treatment. If possible, prescribe a 
safer medicine, if acceptable to the patient 
Warning level 2
Do not drive without the advice 
of a healthcare professional. 
Read the relevant sections on 
driving impairment in the 
package insert before consulting 
the physician or pharmacist
Category 3
Likely to have a severe 
adverse effect on fitness to 
drive, or presumed to be 
potentially dangerous
Inform the patient about the possible 
impairing side-effects and the negative 
influence on his or her driving ability. 
Urgently advise the patient not to drive. 
Consider prescribing a safer medicine, if 
acceptable to the patient
Warning level 3
Do not drive. After a period of 
treatment, seek medical advice 
about the conditions to start 
driving again
Note: (1) The assigned categories relate to the acute or first-time use of the medicine (at the start of treatment).
Based on this, 1 541 medicines available on the EU market were categorised. The distribution 
within the categories was as follows: category 0, 50.3 %; category 1, 26 %; category 2, 
11.2 %; category 3, 5.8 %; multiple categories, 4.4 %; and ‘depending on the medicine in 
combination’, 2.3 %. Thus, about 17 % of medicines on the EU market had a relevant influence 
on driving skills.
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It is not easy to adapt all the different current national approaches to this new categorisation 
system. Nevertheless, discussions with the Pharmacovigilance Working Party (PWP) of the 
Committee for Medicinal Products for Human Use have led to a consensus on developing a basic 
two-level framework for warnings in the patient information leaflet in the package, both for 
medicines without a potential relevant influence on driving (no, negligible or minor influence) and 
for medicines with a potential relevant influence on driving (moderate or major influence). At the 
time of writing (December 2012), the responsible Commission services had not yet endorsed this 
agreement and so the PWP had not received the mandate to implement it.
It is normal for information on the side-effects of medicines, such as effects on driving ability, to be 
included in the patient information leaflet inside the package. However, some European countries 
now include a pictogram on the medicine package itself that conveys the risks when driving. To 
understand the effectiveness of these, a total of 1 006 patients visiting pharmacies in Spain and the 
Netherlands were asked their opinions on two pictograms that distinguished between different 
levels of impairment, one with warning triangles, used in France (Figure 5), and another with 
ratings developed by the DRUID project (Figure 6).
Figure 5. Triangle model pictogram (France)
Figure 6. Rating model pictogram (DRUID)
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The studies showed that both pictograms were effective in communicating risk. A large majority of 
patients (70–80 %) considered these pictograms clear and self-explanatory, with a preference for 
the DRUID rating model. Furthermore, 78 % of the patients stated that they would drive less 
frequently or not at all (depending on the medicine category) if confronted with the pictogram on 
the medicine box.
The DRUID project also reviewed national guidelines for prescribing and dispensing medicines that 
might affect driving performance to see how they varied across Europe. It aimed to examine how 
qualified personnel such as physicians and pharmacists could or should play a role in helping 
patients understand the risks of driving while taking psychoactive medications. The project found 
that the guidelines are typically recommendations, rather than strict and binding regulations, and 
that the role, responsibilities and tasks of physicians and pharmacists are not defined uniformly. 
Nevertheless, a common recommendation is that physicians and pharmacists should give their 
patients the most appropriate advice on medicines and their effect on driving performance and 
should assist the patient with the decision whether or not to drive while using medicines. However, 
studies of physicians and pharmacists in Belgium, Spain and the Netherlands showed that over 
two-thirds received no education regarding the effects of medicines on driving during their 
academic studies or professional postgraduate education.
To address this, the DRUID project developed a software package that could be integrated into the 
software used in the physicians’ and pharmacists’ daily practice to implement DRUID prescribing 
and dispensing guidelines. After 6 months of using this, there was a positive change in knowledge 
and behaviour in both professional groups, although it was more pronounced among pharmacists, 
perhaps as they are more used to instructing patients on the side-effects of medicines. This shows 
that such decision support tools are welcome and usable and can improve the quality of 
healthcare.
The details of the research and findings can be found in the deliverables from Work Packages 4 
and 7 — see Annex 3.
What limits should policymakers set for psychoactive substances 
in drivers?
The project aimed to develop recommendations concerning legal measures to combat drink- and 
drug-driving. To do this, an extensive literature study was carried out, focusing both on theories of 
sanctioning and also on empirical research results on drink- and drug-driving sanctioning (e.g. 
general deterrents such as policies and changes in the law and specific deterrents such as jail 
sanctions and fines). A questionnaire to gather information on legal regulations regarding drug-
driving and legally imposed cut-off limits for illicit psychoactive substances was distributed in the 
European Member States, Croatia, Norway and Switzerland, complemented by official data from 
the EMCDDA. Finally, DRUID experts in the fields of experimental studies, epidemiology and 
toxicology collaborated closely to give recommendations on how to determine legal cut-off limits. 
For this, the experts had to consider issues such as the data behind estimations of accident risk, the 
pros and cons of different research methods, the criteria to define cut-off limits, the different 
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substances and their prevalence, metabolites, combined consumption, medicinal use, and the 
different analytes and bodily fluids (whole blood, plasma, oral fluid, dried blood spots) and 
conversion factors between them.
There are three groups of options available to policymakers when setting limits: setting legal limits, 
zero tolerance and impairment. Those setting legal limits, often known as ‘per se laws’, establish a 
fixed substance limit (e.g. BAC): any driver in whom the concentration of a particular substance 
reaches or exceeds the legal limit is considered to have broken the law without there being a need 
to demonstrate any further signs of impairment. Zero tolerance laws are a specific subgroup of laws 
setting legal limits with a substance concentration of zero. This means that any detectable amount 
of relevant psychoactive substances in the driver’s body fluids has to be considered as a violation 
of the law. In the case of impairment legislation, it must be proven in each case that the driving 
skills of the driver were adversely affected. Signs of impairment will usually be observed during the 
police stopping procedure, during which most European countries use fixed testing protocols. These 
options were considered for the three groups of psychoactive substances: alcohol, medicines and 
illicit drugs.
Laws setting legal limits are the most effective approach to combat drink-driving. The standard legal 
limit should not be higher than a BAC of 0.5 g/l, as recommended by the EU to all Member States 
(Commission Recommendation 2001/115/EC of 17 January 2001). The effectiveness of legal limit 
BAC values below 0.5 g/l is very much dependent on the prevailing societal, legal and political 
environment and the enforcement activity of the police in that Member State. The enactment of 
lower legal BAC limits for some risk groups (e.g. professional drivers, drivers of large vehicles or 
drivers of vehicles carrying dangerous goods) should be considered with respect to the specialities 
of these driver groups; the above Commission Recommendation proposed a maximum BAC 
threshold of 0.2 g/l. A zero tolerance approach seems to be effective for young and novice 
drivers. Mixed intoxication through alcohol and other psychoactive substances (including 
medicines) is a much greater threat to road safety than the sole consumption of these substances. 
Consequently, the legal BAC limit in those cases must be lower than that for the consumption of a 
single substance.
With regard to medicines, the project concluded that it is not reasonable to define cut-off values for 
patients undergoing long-term treatment. Even high doses may lead to few effects. There is no clear 
inter-individual correlation of dosage with impairment. Legal measures should be taken only after a 
traffic incident and sanctions should be triggered by impairment; such a policy may also address 
the recreational use of medicines. No distinction should be drawn between patients undergoing 
substitution treatment and patients receiving other medicinal treatments — fitness to drive should be 
assessed individually in each patient — but addiction to other impairing substances is clearly an 
exclusion criterion for driving. Alcohol increases impairment and interacts adversely with many 
medicines. Hence, drinking, medicine consumption and driving should be separated, and that 
advice should be part of the physician’s consultation.
Establishing limits for driving after taking illicit drugs is more complex than establishing limits for 
alcohol or medicines. At present, 11 countries in Europe use the impairment approach, eight use 
zero tolerance or legal limits and nine combine these two approaches into a two-tier system. The 
zero tolerance or legal limit approach appears to be more promising, particularly as, until now, the 
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effectiveness of enforced impairment laws has been relatively low. Police officers should be able to 
detect all signs of impairment during roadside checks in order to register them in official protocols, 
which form the basis for a court conviction, and to be able to do this police officers will need 
regular special training.
To date, all countries that have legal limits use analytical cut-off limits, i.e. the lower concentrations 
that can be reliably identified by forensic laboratories. In some countries these are the lowest limits 
of quantification of the forensic laboratories; in others they have been established by experts. Some 
countries take into account the effects of the substances, for example by measuring only the active 
component of cannabis, THC, instead of the inactive metabolite. There are three classes of 
substance thresholds that may be used to determine cut-offs:
1.  ‘risk thresholds’: concentrations in blood that indicate a certain risk of accident or impaired 
driving;
2.  ‘lower effect limits’: the lowest concentration at which an effect on driving is observed, thus 
proving that there is a negative impact on driving;
3.  ‘limit of detection’: based on technical limitations in order to guarantee a valid and reliable 
analytical result, although this does not necessarily indicate recent consumption of the 
psychoactive substance or being under the influence of it.
One of the problems of using lower effect or risk threshold limits for illicit drugs is effectively 
establishing the dose that can be taken while still remaining under the limit. The establishment of 
lower effect limits does not mean that the use of illicit drugs when driving is accepted. In some 
countries (e.g. Finland and Sweden), the presence of drugs below the limit set for driving will lead 
to prosecution for drug use. Another problem is that, in determining ‘lower effect limits’ for stimulant 
drugs such as amphetamines and cocaine, the correlation between drug concentration and the risk 
of traffic accidents/impairment is variable or insufficiently documented. Inactive metabolites may 
also need to be included in the legislation when the parent drug is unstable and is metabolised 
very rapidly; for example, cocaine. If a country decides to include inactive metabolites such as 
benzoylecgonine, the cut-off should be so high that cocaine consumption a long time ago (e.g. 12 
hours, as the time for post-acute effects) can be excluded.
It is not realistic to develop cut-off limits for all existing medicines and illicit drugs. The proliferation 
of new psychoactive substances complicates the matter further. The legal limit law, listing a few 
substances, may be combined with an impairment law, in which all other impairing substances are 
covered. In this scenario, there is a quick and simple procedure for the most common drugs and a 
more elaborate one for the less frequent cases, including medicines and combinations of drugs. For 
drug combinations, some experts recommend using limits of quantification rather than legal limits 
set at the lower effect. However, to gain the compliance of the population, clear legislation, which 
differentiates drug and traffic policy, will need to be implemented.
To determine risk thresholds for the most common illicit drugs, the DRUID partners set out to find, for 
each substance, the concentration in blood at which the accident risk is equivalent to the risk 
associated with 0.5 g/l BAC, this being the limit at which alcohol-impaired driving is tolerated in 
most European countries. This implies that a certain level of risk is acceptable, and so a similar 
emcdda.europa.eu
34Findings from the DRUID project
approach could also be used to define threshold quantities of illicit drugs in the blood. However, in 
the epidemiological studies the number of drug-impaired drivers was so small that it was possible to 
calculate risk thresholds only from the meta-analysis. In the case of THC, the epidemiological, 
experimental and meta-analytical approaches resulted in rather low risk estimations, so THC seems 
to be much less impairing and risky than most of the other substances examined. In the meta-
analysis a serum concentration of 3.8 ng/ml THC (≈ 2 ng/ml in whole blood) was shown to be as 
impairing as 0.5 g/l alcohol. This value could be an empirical basis for a threshold discussion, but 
such a discussion should address the question of whether determining risk thresholds as equivalents 
to 0.5 g/l BAC is politically feasible, partly because a BAC of 0.5 g/l is not a legal limit in all 
European countries. Some Member States have lower alcohol limits and some are currently 
discussing a zero tolerance approach, and therefore risk threshold calculations for THC would have 
to be adapted accordingly.
The details of the research and findings can be found in the deliverables from Work Package 1 — 
see Annex 3.
How well do roadside detection systems work?
In the early 2000s, the EU research projects Rosita and Rosita-2 established standards for on-site 
screening devices for drugs and investigated whether the testing devices at that time, screening oral 
fluid or urine, could achieve a standard of accuracy such that they could be used by traffic police 
with confidence. The results showed that those devices required more development. Five years later, 
the DRUID project once again evaluated on-site screening devices (all of which screened oral fluid, 
which provides better information on recent drug use), in both practical and analytical terms. 
Bearing in mind the time and money that the use of such devices requires, the project also 
evaluated clinical signs of impairment, such as bloodshot eyes, uncoordinated movements and 
aggressive behaviour, to see if these could be used to accurately pre-screen drivers before use of 
the oral fluid screening devices.
The practical test of the devices considered aspects such as the time taken to collect a sufficient oral 
fluid sample, the time taken to analyse the sample, hygiene aspects and the officers’ impressions of 
the reliability and simplicity of the test. Thirteen roadside testing devices were used in six countries 
by trained police officers in 2 960 roadside tests. As a result, eight devices were evaluated as 
‘promising’ for roadside use by police officers, and these were then submitted for analytical 
evaluation.
The analytical evaluation was carried out in Belgium, the Netherlands and Finland from October 
2007 to December 2009. Tested substance classes were amphetamine(s), methamphetamine, 
MDMA, cannabis, cocaine, illicit opioids and benzodiazepines. Study populations consisted of 
randomly selected drivers from the DRUID roadside surveys, drivers suspected of driving under the 
influence of drugs, patients in drug treatment centres and rehabilitation clinics, and customers of 
coffee shops.
At the same time, a checklist for clinical signs of impairment was evaluated in order to determine if 
visible signs of impairment can be used as preceding selection criteria for performing an on-site 
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test. The checklist comprised 24 different symptoms, based on several existing checklists, e.g. one 
developed for the German police and previously used in the European IMMORTAL (Impaired 
Motorists, Methods of Roadside Testing and Assessment for Licensing) project.
How do you test a test? Sensitivity, specificity and accuracy
To find whether a test is correctly able to identify those people who are positive and those who are negative, 
statisticians use the terms ‘sensitivity’, ‘specificity’ and ‘accuracy’. Sensitivity refers to the proportion of 
positive people who are correctly identified as positive. Specificity refers to the proportion of negative 
people who are correctly identified as negative. The two are combined to calculate the accuracy. Specificity 
of 100 % would mean that no driver who has refrained from taking drugs would be accused of drug taking 
(‘false-positive’), while 100 % sensitivity would mean that no driver who has recently taken drugs would be 
declared clean (a ‘false-negative’).
The results of the evaluations of the checklist for clinical signs of impairment were not very 
promising. The indicators proved to be effective mainly in cases of high concentrations or very 
recent use. The pupil reaction test was the best predicting parameter, especially for amphetamines 
and THC. The checklist scored a low sensitivity value (Dutch study) and an even lower correlation 
of symptoms with actual presence of drugs (Belgian study) and in some cases there were difficulties 
in correlating the symptoms with actual drug use owing to insufficient data collection (Finnish study). 
More experience, better training and selecting times and locations with a high incidence of 
drug-driving may improve the effectiveness of such checklists.
The performance of the eight promising oral fluid screening devices was assessed, based on 
sensitivity, specificity, accuracy, positive predictive value and negative predictive value, for the 
individual substance tests of the device. These were assessed based on both DRUID and 
manufacturer cut-off limits. Sensitivity, specificity and accuracy performance values of 80 % or 
more were set as a desirable target value. In order to obtain statistically valid calculations, it was 
determined that at least six positive (in the case of sensitivity) or six negative (in the case of 
specificity) cases were needed.
The results were as follows:
Drug group Sensitivity range (%) Specificity range (%) Accuracy range (%)
Amphetamine  0–87 91–100 84–98
Cannabis 11–59 90–100 41–82
Cocaine 13–50 99–100 86–100
Opioids 69–90 81–100 75–99
Benzodiazepines 48–67 94–100 77–100
None of the tests reached the target value of 80 % for sensitivity, specificity and accuracy for all 
the separate tests they comprised. Not enough positive cases were gathered to successfully 
evaluate any of the methamphetamine, MDMA or phencyclidine (PCP) tests for the devices in which 
these were included. In comparison with the devices tested in the project Rosita-2 in 2003–05, 
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minor developments can be seen in test precision for amphetamines, opioids and benzodiazepines, 
but no significant improvements can be seen for cannabis and cocaine. Nonetheless, in general, 
devices can be expected to improve in performance as the field develops.
In addition to evaluating the individual substance group tests, an overall evaluation was performed 
as a measure of the usefulness of the devices in police checks to identify drug drivers generally, 
even if they could not correctly identify which drug was actually present. In this case, any positive 
drug screening result was viewed as valid, providing that the confirmation sample contained one of 
the DRUID substances analysed. For example, if a test kit declared a positive finding for 
amphetamine, but the confirmation sample tested positive only for cannabis, it would be recorded 
as a valid result. In this overall evaluation, three of the devices performed at > 80 % for sensitivity, 
specificity and accuracy (Figure 7).
When assessing the evaluation results above, the prevalence of drugs in the populations studied 
should be considered; higher prevalence can lead to enhanced sensitivity, whereas lower 
prevalence can lead to enhanced specificity and higher accuracy. If the suitability of the device is 
considered based on the above results, the type and prevalence of drugs within the population for 
which the device is intended to be used should be taken into account; for example, the overall 
evaluation performance of the DrugWipe 5+ can be largely attributed to its strong individual 
performance in the amphetamines test and the prevalence of these substances in the Nordic study 
population.
Collecting evidence: dried blood spot analysis
Once a driver has screened positive, collecting blood for evidence can be complicated. Whole 
blood and plasma samples should be taken only by medical personnel, and this can be difficult in 
Figure 7.  Sensitivity and specificity of the oral fluid screening devices for any positive result
Cozart DDS
DrugWipe 5+
Oratect III
BIOSENS Dynamic
0
20
40
60
80
100
60 70 80 90 100
Specificity
Se
ns
iti
vi
ty
%
%
OraLab6
Rapid STAT
DrugTest 5000OrAlert
emcdda.europa.eu
37Findings from the DRUID project
drivers with limited venous access, such as injecting drug users. Intoxicated drivers are not always 
calm. Blood should be transported and stored in special low-temperature conditions to stop the 
samples degrading and to avoid the risk of infection. The DRUID project took advantage of a 
unique opportunity to test the possibility of an alternative option for determining the presence of 
analytes in blood.
For years, dried blood spot (DBS) analysis has been routinely used for screening newborn infants 
for congenital metabolic disorders. Analysis of DBS specimens for drugs has become feasible with 
the advent of increasingly sensitive mass spectrometry techniques, and is now a valuable tool in 
therapeutic drug monitoring. DBS is a less invasive alternative to taking a blood sample; it can be 
prepared using capillary blood after a finger or heel prick by non-medical personnel. A spot of 
whole blood is dried onto a custom-made card, which is then folded and left to dry at room/
ambient temperature for 3 hours. Roadside sampling should reflect the actual blood concentration, 
and hence driver impairment, at the time of being stopped by the police or at the scene. DBS 
samples can be transported and stored in sealed envelopes with desiccant packs and can be sent 
by regular mail.
The project examined the feasibility and accuracy of detecting the most common substances used by 
drivers using DBS analysis compared with analysis of whole blood samples. In fact, by using liquid 
chromatography–mass spectrometry, all investigated analytes could be determined with sufficient 
lower limits of quantification. The evaluation data showed no significant differences in precision: all 
substances investigated in the presented studies could be determined in a DBS as reliably as in a 
whole blood specimen. Thus, the project demonstrated that DBS drug analysis can be regarded as a 
valuable and inexpensive alternative to the determination of substances in whole blood. Such use of 
DBS could greatly facilitate blood analysis in drug-driving cases in the near future.
The details of the research and findings can be found in the deliverables from Work Package 3 
(DBS in Work Package 1) — see Annex 3.
What are the costs and benefits of investing in drug-driving 
enforcement?
As it is known that some drivers are under the influence of drugs, and some of these greatly 
increase the risk of serious injury or death in accidents, the logical reaction is to demand an 
increase in enforcement and detection. The policy goal of increased enforcement, targeting driving 
under the influence of psychoactive substances, would be to increase the benefits to society (reduce 
societal costs) through a deterrence effect that should reduce driving under the influence of 
psychoactive substances, and subsequently reduce the toll of fatalities and injuries. However, there 
are also costs involved in an increased level of enforcement, such as the costs of screening and 
control equipment and police time, as well as additional medical and judicial costs in the case of 
suspicions and convictions. These would also vary according to the device used. Therefore, as part 
of the DRUID project a cost–benefit analysis (CBA) was carried out, assessing to what degree 
increased enforcement against driving under the influence of drugs would be profitable in 
economic terms for society, together with an assessment of which of the existing devices for such 
enforcement would be the most profitable to use.
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A benefit–cost ratio was estimated according to the formula:
Benefit–cost ratio =
   Present value of all safety benefits 
 Present value of implementation costs and time used
In addition to the CBA and estimates of net benefits and the benefit–cost ratios of increased traffic 
police enforcement, the study also included a cost-effectiveness analysis.
The CBA aimed to answer two questions:
1.  To what degree is the enforcement of legislation against driving under the influence of drugs 
profitable in economic terms for society?
2.  Which of the existing devices for such enforcement is the most profitable to use?
The basic idea of the CBA model is that a particular scenario or group of scenarios is compared 
with the reference situation or baseline, which is a continuation of the current situation. Thus, CBA 
compares economic benefits and costs arising from the implementation of specific policies/projects 
with a ‘do-nothing’ reference/baseline. The model was completed with data from three countries 
(Belgium, the Netherlands and Finland).
DRUID considered three scenarios in CBA: a small (50 %), medium (300 %) and large (1 000 %) 
increase in the enforcement of drug/medicine oral fluid testing, while maintaining the current level 
of alcohol enforcement. As the CBA was applied to different countries, with different prevalence of 
the different drugs/medicines (and alcohol), the effect of the prevalence was also taken into 
account. The prevention of deaths and serious injury brought about by increased enforcement is 
balanced against the time-consuming process of on-site oral fluid screening, the rather high cost of 
the devices and the relatively low sensitivity for cannabis (the most common illicit drug), which 
would imply a high number of potentially dangerous false-negatives. One further element in the 
scenarios was to recalculate the 300 % drug enforcement increase together with a 10 % reduction 
in alcohol enforcement. This aimed to simulate an adjustment of random alcohol breath testing to 
maintain current overall enforcement levels/resource use, i.e. to transfer a share of alcohol 
enforcement to drug enforcement. In this way the project could compare the effects of an increase 
in resources with a redistribution of resources.
The calculation differentiated between road users, who would benefit from safety improvements 
(due to enforcement) but lose time when being tested (negative benefits), and the public sector, 
which would cover the costs of the enforcement efforts, prosecution, etc., by the police, the courts 
and ministries.
The calculations were based on the following data:
•   the effects of enforcement, i.e. the reduction in accidents, fatalities, injuries and material damage 
resulting from this kind of enforcement;
•   the costs of (or positive benefits of preventing) accidents, fatalities, injuries and material damage;
•   the costs (negative benefits) of road users’ time;
•   the costs of devices/equipment;
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•   the costs of police time;
•   the costs of laboratory analyses;
•   the costs of the judicial system.
The basic requirement for increased drug enforcement to be considered efficient is a benefit–cost 
ratio of 1.5 or higher, while a benefit–cost ratio of between 0 and 1 indicates that the cost of 
increased enforcement is higher than the benefit. The benefit–cost ratios were calculated as follows:
Enforcement increase Belgium Netherlands Finland 
  50 % 8.04 19.60 1.27
 300 % 5.09 13.74 0.79
1000 % 1.82 5.04 0.28
The analysis of scenarios in the three countries shows that increased drug control would be most 
profitable for the Netherlands and least profitable for Finland. This is logical in terms of the 
baseline enforcement level, as in Finland the level of drug enforcement (tests per 100 000 
inhabitants) is already 25 times higher than that in the Netherlands. In the Netherlands an even 
larger increase might be cost-efficient.
This finding was supported by a simulation of the three countries increasing their level of 
enforcement to arrive at a comparable enforcement level (‘control density’):
Country Enforcement increase New drug control density Benefit–cost ratio
Belgium 300 % 0.108 % 5.09
Netherlands 2 000 % 0.121 % 2.70
Finland 10 % 0.160 % 1.23
However, this conclusion became more nuanced when comparing the net benefits for a 300 % 
increase in drug enforcement with extra resources (i.e. maintaining ‘100 % alcohol’ enforcement) 
with those for a 300 % increase in drug enforcement funded by a transfer of existing resources 
from alcohol to drug enforcement (i.e. a reduction to ‘90 % alcohol’ enforcement):
Belgium Netherlands Finland
90 % alcohol
100 % 
alcohol
90 % alcohol
100 % 
alcohol
90 % alcohol
100 % 
alcohol
Road users net 
benefits (EUR) 
15 162 061 23 700 208   –327 813  9 975 499 1 052 860  3 557 730
Public sector net 
benefits (EUR)
 8 215 102  6 833 944 11 164 565  3 722 058 5 288 350 –1 796 535
Total net benefits 
(EUR) (1)
20 075 601 27 232 590 10 359 936 13 220 740 3 244 818 –1 335 197
Benefit–cost ratio 5.09 13.74 0.79
Note: (1) Total also takes into account fines paid by offenders, not included in this table.
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In these simulations, maintaining alcohol enforcement while increasing drug enforcement led to an 
improved benefit–cost ratio in those countries with lower enforcement levels. While the benefit–cost 
ratio for the increase in drug enforcement funded from alcohol enforcement is not comparable to 
the case when maintaining alcohol enforcement, the net benefits can be compared. For the alcohol 
enforcement reduction case (‘90 % alcohol’), the denominator is then normally rendered negative 
because of an overall enforcement cost reduction, and then the benefit–cost ratio ceases to be a 
robust indicator of cost efficiency. However, estimated net benefits are robust to any changes in 
benefits and costs, and thus can be compared between ‘90 % alcohol’ and ‘100 % alcohol’ cases. 
The net benefits calculated overall are still financially positive when funding increased drug 
enforcement with 10 % reduction in alcohol enforcement, even if in the Netherlands and Belgium 
they are lower than net benefits when maintaining alcohol enforcement. However, when the shares 
of the benefits distributed between road users and the public sector are closely examined, one can 
see that the overall increase in benefits comes at the cost of net benefits to the road user, i.e. at the 
cost of safety on the roads.
The final conclusion is that increased drug-driving enforcement based on roadside oral fluid 
screening is potentially cost-beneficial. However, this is by no means straightforward, and depends 
on the initial levels of both drug prevalence and law enforcement. If prevalence in traffic is low, 
there are fewer lives to be saved by testing. Regarding enforcement, these models show that the 
higher the enforcement level is to begin with, the lower the overall net benefits to society from any 
increase, and they may even decrease. The shares of those benefits within society should also be 
considered. Road user net benefits will certainly increase if the level of law enforcement for alcohol 
is maintained while law enforcement for drugs increases; in contrast, reducing law enforcement on 
alcohol to fund drug enforcement may actually have a negative impact on road safety. Therefore, 
to answer the two questions posed by the CBA, the first priority of enforcement should always be 
alcohol; other drugs take second place. The characteristics of the problem on a national level (e.g. 
the prevalence levels of different drugs) will determine the focus of, and devices used in, drug 
enforcement; devices that perform above average will contribute to a higher benefit–cost ratio than 
those that perform below average.
The details of the research and findings can be found in the deliverables from Work Package 3 — 
see Annex 3.
How effective is withdrawal of the driving licence?
Withdrawal of the driving licence refers to the removal of permission to drive. Generally, this may 
take one of two forms. In the first, the licence is withdrawn for a fixed period and automatically 
reverts to the driver at the end of that period. In the other, the driver has to pass some form of test 
before regaining the licence. The terms ‘driving ban’ and ‘licence withdrawal’ may be used, but 
these do not have a common interpretation across Europe.
Licence withdrawal is a sanction that is both a form of general deterrent and a form of special 
deterrent. A general deterrent aims to discourage others from committing the same crime as the 
offender was punished for, or a similar one, through the fear of punishment. Here, it is referred to 
as distinct from general prevention, which aims to strengthen public approval of the law and its 
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enforcement (12). A special deterrent aims to bring about a change in the behaviour of the accused 
and convicted person through the impact of the sentence. This is distinct from special prevention, 
which aims to rehabilitate the offender through a change in behaviour as a result of a change in 
attitude, and not only through the fear of penalties.
To understand the current conditions regarding licence withdrawal in the EU, all 27 Member States 
and three non-EU countries were sent a special DRUID questionnaire about existing legal 
regulations and sanctioning practices. In most countries (24/30), driving while above the legal limit 
of alcohol leads to withdrawal of the driving licence. Two-thirds of the countries (19/30) have a 
withdrawal sanction for driving under the influence of both alcohol and drugs. Twelve of the 30 
countries have withdrawal sanctions for all three groups of psychoactive substances, i.e. alcohol, 
drugs and medicines.
Considering the different periods involved, about two-thirds of the countries withdraw the licence 
for a temporary period. In 10 countries, conditional withdrawal is possible, for example the 
withdrawal is effective at weekends or outside a certain geographical area (beyond the place of 
work/school/doctor’s practice). Eight countries have the legal potential to reduce the withdrawal 
period after the driving licence has been withdrawn, for example after participation in a treatment, 
rehabilitation or ignition interlock programme. The withdrawal period can also be reduced for 
some other reasons, such as personal, professional or social circumstances, the character of the 
applying offender, his or her conduct after conviction or the nature of the offence.
For alcohol, there are sizable differences in withdrawal periods among the European countries. These 
depend on BAC limits, which vary considerably across Europe. In some countries, accidents occurring 
when the driver is under the influence of alcohol, as well as recidivism, i.e. another drink-driving 
offence within a certain time period, will lead to an extension of the withdrawal period. However, for 
drugs, only 22 out of 30 countries provided information to the DRUID researchers on withdrawal 
periods. In eight countries, licences could be withdrawn for drug-driving for periods up to 6 months; 
four countries indicated withdrawal periods between 6 and 12 months; five countries indicated 
periods between 12 and 24 months; and five countries indicated periods of longer than 24 months.
As a second step, to understand the implementation and effectiveness of these regulations and 
practices, findings from about 60 empirical primary studies and non-empirical studies on the general 
and special deterrent/preventive impact of withdrawal were analysed. Country expert workshops 
were carried out with experts from ministries of justice, the courts and administrative authorities, 
ministries of health, the rehabilitation system, the police and ministries of the interior, and ministries of 
transport. International expert workshops focused on licence withdrawal for specific problem groups, 
namely drivers undergoing substitution treatment and long-term medication treatment.
The analysis of the empirical literature revealed that the general deterrent approach includes three 
main factors that often overlap:
•   the certainty of the punishment (including the risk of detection and the probability of the case 
being dropped before conclusion);
(12) General prevention is closely related to the EMCDDA’s concept of environmental prevention.
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•   the severity of the punishment (including the legal threat of sanctions and how they are imposed 
— by judicial or administrative practice);
•   the celerity, or swiftness, of the punishment (how quickly after the offence is committed the 
punishment is applied).
The main general deterrent factor is the perceived risk of detection — not the real risk. In most 
cases, the perceived risk is higher than the real risk, and it is primarily influenced by the intensity of 
the media coverage of police enforcement operations. Laws without any discretion for the 
authorities are major factors in increasing the probability of sanctioning at the end of the process. 
However, this element must be accompanied by a high level of (real) risk of detection to achieve 
significant levels of general deterrence. Empirical primary findings indicate that increasing the 
certainty of sanctioning is much more effective than increasing the severity of sanctioning. The 
celerity of punishment is — besides the certainty of punishment — a further important deterrent 
factor.
From this, the project concluded that the certainty and celerity of sanctioning are crucial for both 
the general and the special deterrent impact of sanctions — above all the immediate withdrawal/
suspension of the driving licence and a high level of perceived risk of detection. Driving licence 
withdrawal has been shown to be a greater deterrent than other sanctions (e.g. imprisonment or 
fines). Social disapproval, especially from peers and friends and particularly with adolescent 
offenders, seems to have a much greater impact than formal legal consequences. Nevertheless, the 
effectiveness of the severity of sanctioning is limited. The duration of withdrawal should be set 
between 3 and 12 months; shorter or longer periods do not seem to have a deterrent impact, and 
a longer withdrawal period generally leads to an increase in non-compliance and thus offenders 
driving without a licence as they try to manage their daily lives. Combining withdrawal with 
rehabilitation/treatment appears to be a more effective deterrent than the sole imposition of either 
measure. Conditional withdrawal, supporting a reintegration process, can be applied together with 
rehabilitation/treatment measures and also with regular medical checks and/or installation of an 
alcohol ignition interlock, which allows the vehicle to start only when no alcohol is detected.
It was not possible to make a final recommendation on either an administrative or a criminal 
procedure. The advantages of an administrative procedure are the celerity and certainty of 
sanctioning (especially in the case of legislation setting legal limits); the disadvantages of a criminal 
procedure are related to the considerable differences in the severity of the imposed sanctions.
Recommendations for specific problem groups included the following:
•   For drivers found under the influence of alcohol, a graduated system of withdrawal and 
additional measures — depending on the BAC level — should be introduced. Driver assessment 
and rehabilitation should be legally regulated and based on defined criteria. An alcohol ignition 
interlock could be offered as an option in exchange for a reduced length of licence suspension 
and should be offered in combination with at least strict medical counselling or even 
psychological support.
•   For drivers found under the influence of drugs, the general deterrent principles for alcohol are 
also valid.
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•   For patients undergoing long-term treatment with psychoactive medicines, legal measures should 
be taken only after an incident in traffic; impairment is the key indicator for sanctioning. A model 
of conditional licensing, based on an assessment of fitness to drive, is to be recommended. For 
patients in substitution treatment, each will need to be assessed individually regarding fitness to 
drive. It is recommended that a conditional licence, based on the assessment of fitness to drive, is 
combined with follow-up controls — above all focusing on abstinence from the parallel 
consumption of other drugs.
The details of the research and findings can be found in the deliverables from Work Package 6 — 
see Annex 3.
How effective are driver rehabilitation schemes?
The aim of a rehabilitation scheme is to allow the driver to return to the road while minimising the 
likelihood of reoffending. The DRUID project included comprehensive reviews of international 
literature on the topics of identifying different types of drink- and drug-driving offenders, existing 
assessment procedures and rehabilitation measures, and the options for addicted/dependent 
offenders. Many organisations that provide driver rehabilitation services in the different countries 
contributed to investigate the measures currently implemented in Europe.
In Europe, drink- and drug-driving assessment is primarily carried out in the frame of the decision 
on fitness to drive. It is mostly a multidisciplinary approach, covering medical, psychological and 
social aspects. Objective parameters such as BAC or prior offences can serve as criteria for deeper 
assessments or even directly for specific driver rehabilitation. There is no uniformity across Europe 
regarding the implementation of drink- and drug-driving rehabilitation. Five selected European 
countries (Austria, Belgium, Germany, France and Hungary) served as examples for current 
approaches; national regulations are established for different aspects of drink- and drug-driving 
rehabilitation. Regarding access to such rehabilitation programmes, the survey showed that 
European countries use very different approaches, ranging from voluntary, through recommended, 
up to obligatory participation.
At least 47 providers, mainly non-governmental, private organisations in 12 European countries 
(Austria, Belgium, Germany, France, Italy, Hungary, the Netherlands, Poland, Portugal, Sweden, 
Switzerland and the United Kingdom) carry out driver rehabilitation services on a regular basis. In 
total, 87 driver rehabilitation programmes were found, comprising 53 for drink-driving offenders, 
21 for drug-driving offenders and 13 for mixed groups (drink-driving/drug-driving/other traffic 
offenders). All the above-mentioned countries offer programmes for drink-driving offenders, and 
four of them (Austria, Belgium, Germany and Portugal) also offer programmes for drug-driving 
offenders. The vast majority of driver rehabilitation providers do not offer treatment programmes for 
substance-dependent offenders.
The literature review identified 61 studies on the effectiveness of rehabilitation programmes of drink- 
and drug-driving offenders. Group intervention programmes were developed and optimised for 
drink-driving offenders. Driver rehabilitation programmes for drink-driving offenders are based on a 
rather long-term tradition in development and practical application in Europe. The ‘European standard 
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group intervention’ can be described as follows: a course with 6–12 participants, using a 
psychological therapeutic approach with educational elements, led by a qualified course leader, often 
a psychologist. The programme lasts several weeks and has the same course leader and participants. 
An analysis of 36 studies and two reviews (recidivism as evaluation criterion) showed that these 
programmes reduce recidivism by on average 45.5 %, with rates varying from 15 % to 71 %.
To help predict the potential success of a drink-driving rehabilitation course, some 600 drivers were 
analysed: 300 (matched control group) who had not reoffended following such a course, against 
300 who had reoffended. Based on this, the project deduced that drink-driving offenders with the 
following risk profile might not benefit from a driver rehabilitation course:
•   those having high BAC levels at the current offence or refusing the breath test;
•   those having prior drink-driving offences (i.e. the current one is not the first) and consequently 
having longer periods of driving licence suspension;
•   those having a habitual drinking pattern in the past and, in spite of past or current periods of 
abstinence, having increased alcohol tolerance, therefore having felt less impaired at the time of 
the drink-driving offence;
•   those who deny having any alcohol-related health problems, are smokers and are less aware of 
their own health status;
•   those demonstrating an unrealistic self-perception and less self-reflection, whereby alcohol-
related risks in traffic are underestimated;
•   those not living in a partnership;
•   those having been assessed as having an increased risk of reoffending by a qualified expert 
(traffic psychologist).
It was found that drink- and drug-driving rehabilitation helps to prevent people from impaired 
driving and restores their mobility in a safe way, and therefore driver rehabilitation should be an 
integrated part of a comprehensive countermeasure system. To assist with this, the project 
developed Europe-wide standards and recommendations of good practice for drink- and drug-
driving rehabilitation measures. These were developed into a user-friendly tool (Driver Rehabilitation 
Evaluation Tool, DRET) for implementation, assessment or evaluation of existing or new driver 
rehabilitation systems or programmes. It was considered that this could be the starting point for a 
European networking and documentation process for driver rehabilitation measures, perhaps 
leading to the formulation of main procedures at an EU level.
Various recommendations were also made on the assignment of drivers to driver rehabilitation 
courses as follows. Legal regulation of driver rehabilitation participation should be established in 
order to systematically bring offenders to intervention. It is important to link participation in driver 
rehabilitation and licensing procedures, for example participation in driver rehabilitation as a 
precondition for a reduction in the suspension period or for reinstatement of the licence. Formal 
criteria for directly assigning drink- and drug-driving offenders to driver rehabilitation (or at least to 
counselling) should be established in order to initiate awareness of the problem and screen for a 
severe alcohol or drug problem; the criteria proposed were a high BAC level (above 1.6 g/l), 
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reoffending within 5 years and refusal of a test. Driver assessment prior to driver rehabilitation 
should be obligatory in cases in which addiction is suspected, in order to match offenders to 
appropriate treatment. Driver rehabilitation participation should be mandatory for high-risk 
offenders, repeat offenders and young (novice) drivers.
However, it was emphasised that rehabilitation options should vary according to the needs of 
different offenders. The intensity of intervention should increase with the severity of the problem 
behaviour. Addicted offenders should be at least separated from non-addicted offenders. If 
possible, drink- and drug-driving offenders should not be mixed. European standard group driver 
rehabilitation interventions can be recommended as a good practice example for non-addicted 
drink- and drug-driving offenders. Exchange of information between experts from driver 
rehabilitation interventions and addiction treatment should be encouraged. Alcohol ignition 
interlock programmes can be effective for drink-driving offenders in combination with rehabilitation.
As part of the DRUID project the quality-related requirements of driver rehabilitation were also 
considered, and it was recommended that quality management systems should be implemented at 
a European, national and driver rehabilitation provider level. Quality management requirements 
should be established on a legal base in order to achieve uniform quality management standards. 
It was noted that, optimally, these standards would be defined at a European level. Nevertheless, a 
(national) quality management body should also be installed, which is independent and 
authoritative and in a position to execute the operative quality management tasks in driver 
rehabilitation.
The details of the research and findings can be found in the deliverables from Work Package 5 — 
see Annex 3.
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Recommendations of the project
Based on all the empirical research reviewed and carried out by the DRUID project, 
recommendations were formulated for policymakers in the EU and Member States as a scientific 
support to aid in the development of countermeasures to combat impaired driving. These 
recommendations are grouped according to the different classes of psychoactive substance: 
alcohol, illicit drugs and medicines. They are the recommendations of the project experts, and are 
not the official position of the European Commission.
Countermeasures to combat alcohol-impaired driving
Alcohol is still the most prevalent psychoactive substance found in drivers, a problem common to all 
EU Member States. The number of drivers in the general driving population with BAC > 0.5 g/l is 
rather low. Drivers involved in accidents (injured or killed) often have a higher BAC. The combined 
use of alcohol and illicit drugs or medicines is a rare but dangerous problem.
Target groups
•   Young male drivers with a high BAC.
•   Male drivers above 50 years of age.
•   Drivers addicted to alcohol and misusing alcohol.
•   Drivers combining consumption of alcohol and illicit drugs.
Legal regulations
•   The legal BAC limit of 0.5 g/l, established in most European countries, is reasonable, as the risk 
of injury to drivers with a BAC of 0.1–0.5 g/l is rather low. There are no scientific reasons to 
alter this risk threshold.
•   Countries in which the established legal BAC limit is lower than 0.5 g/l have, in general, a lower 
prevalence of alcohol-impaired drivers in the general driving population. Nevertheless, injured 
drivers with a high BAC are still a problem.
•   The establishment of a lower legal limit for specific target groups is promising (e.g. a BAC of 
0.2 g/l for novice and inexperienced drivers, as proposed in the Commission Recommendation 
of 17 January 2001 on the maximum permitted blood alcohol content (BAC) for drivers of 
motorised vehicles (notified under document number C(2000) 4397)).
•   For combined consumption, lower legal limits should be imposed (e.g. 0.0 g/l BAC).
•   Mandatory alcohol testing for drivers involved in accidents resulting in injury should be introduced.
Enforcement strategies
•   Drink-driving enforcement is cost-beneficial. Previous efforts should be continued and, if 
necessary (in countries with high prevalence rates for alcohol), extended.
•   The first priority of countermeasures should always be alcohol; other psychoactive substances 
take second place.
•   To enhance the effect of general deterrence, random police checks are appropriate.
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Rehabilitation measures
•   Driver rehabilitation should be harmonised, for example by applying common European 
standards and using recommendations on good practice for rehabilitation measures developed 
within the DRUID project.
•   Driver assessment and rehabilitation should be legally regulated and based on defined criteria.
•   Drink-drivers should be treated as a separate group from drug-drivers.
•   Non-addicts and addicts should be treated in separate programmes as they require different 
interventions or treatments.
•   Multiple offenders and offenders with a BAC ≥ 1.6 g/l should undergo an examination to 
preclude addiction.
•   An alcohol ignition interlock can be installed during the rehabilitation phase, but it should be 
combined with rehabilitation/treatment and close monitoring.
Licence withdrawal measures
•   The practices of driving licence withdrawal should be harmonised across Europe.
•   Withdrawal is an effective general and specific deterrent. Immediate withdrawal/suspension of 
the driving licence and a high level of perceived risk of detection are decisive. The certainty of 
sanction can be increased by strict enforcement (e.g. implementation of random alcohol and 
drug testing).
•   The withdrawal duration should be between 3 and 12 months.
•   Driver rehabilitation should be an integrated part of driving licence withdrawal.
•   Conditional withdrawal should always be combined with rehabilitation measures and close 
monitoring.
Future needs of scientific investigations
•   The collection of epidemiological data on a regular basis is needed to investigate the problem in 
the long run and to study the development of the prevalence of drink-driving. As case–control 
studies are very time-consuming and expensive and encounter legal and ethical restrictions, it is 
advisable to find alternative study methods of collecting reliable data.
Countermeasures to combat illicit drug-impaired driving
The prevalence of illicit drugs in the general driving population is much lower than that of alcohol. 
Across 13 countries, the estimated mean for all investigated illicit drugs is 1.9 %. Compared with 
alcohol (3.5 %), the prevalence of single illicit drugs is very low. THC and cocaine are the illicit 
substances most frequently detected in most countries. There are large national variations in 
prevalence.
Target groups
•   Young male drivers.
•   Drivers combining consumption of illicit drugs and alcohol and/or several illicit drugs.
•   Drug consumers (of stimulants, e.g. MDMA) with sleep deprivation.
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Legal regulations
•   Regulations should be based on scientific findings; if epidemiological and experimental data are 
not sufficient, an expert team should determine cut-offs taking into account other findings (e.g. 
pharmacokinetic profiles).
•   There should be European harmonisation of drug analyses (e.g. analytical cut-off limits; 
standardised analysing procedures).
•   A risk threshold should be introduced for THC, equivalent to 0.5 g/l BAC, at 3.8 ng/ml serum, 
plus a value to take account of measurement errors and the confidence interval, and minus a 
value to take into account the metabolism between the stop/crash and sampling.
•   For all other psychoactive drugs a two-tier system is advised: legal limits combined with an 
impairment approach. This system combines the advantages of the two legal regulations: a less 
severe sanction when drugs are present above the legal limit and a more severe sanction when 
the driver is also impaired.
Enforcement strategies
•   An increase in drug enforcement is potentially cost-beneficial, especially for countries that 
currently have a low level of enforcement. It may not, however, be beneficial if it is implemented 
at the expense of drink-driving enforcement.
•   The use of only those screening devices that fulfil practical and analytical criteria is advised.
•   Training of police officers (drug recognition expert programmes) to improve drug detection is 
required.
•   Drug detection roadside actions should be developed, taking into account pre-selection by time, 
place and target group (e.g. alcohol-impaired drivers) and national prevalence data.
Rehabilitation measures
•   Driver rehabilitation should be harmonised (see Countermeasures to combat alcohol-impaired 
driving).
•   Driver assessment and rehabilitation should be legally regulated and based on defined criteria.
•   Drug-drivers should be treated as a group, separate from drink-drivers.
•   Distinction should be made between non-addicts and addicts as they require different 
interventions or treatments.
Licence withdrawal measures
•   Withdrawal in the case of drivers consuming drugs regularly should be combined with an 
adequate rehabilitation programme.
Future needs of scientific investigations
•   Collection of epidemiological data on a regular basis is useful following implementation of new 
legal limits or sanctions.
•   Drug recognition expert programmes and impairment checklists should be improved.
•   On-site screening devices that fulfil practical as well as analytical requirements should be 
improved.
•   Dried blood spot (DBS) analysis should be developed further.
emcdda.europa.eu
49Findings from the DRUID project
Countermeasures to combat driving impaired by medicines
Across 13 countries, the estimated mean showed that some of the more frequently used 
psychotropic medicines are taken by 1.4 % of drivers (remembering that not all frequently used 
psychotropic medicines were screened for). The use of medicines varies considerably by country. 
The risk assessment reveals a medium increase in accident risk when driving under the influence of 
psychoactive medicines.
Target groups
•   Healthcare providers and patients.
•   Female drivers over 50 years old, especially drivers using benzodiazepines and medicinal opioids.
Legal regulations
•   No thresholds should be defined for medicines.
•   The most appropriate countermeasure to combat impaired driving is information about the 
possible side-effects. Therefore, a comprehensive information system for physicians, pharmacists 
and patients should be implemented.
•   The four-level classification and labelling system developed as part of the DRUID project should 
be implemented.
Enforcement strategies
•   These are appropriate only if medicines are misused by patients or by healthy drivers. Legal 
procedures and the consequences of misuse of medicines should be in line with policies 
combating driving under the influence of drugs.
•   Strategies should focus on combined consumption of medicines and alcohol.
Rehabilitation measures
•   These should be applied in cases of misuse, similar to the recommendations for combating the 
use of illicit drugs.
Licence withdrawal measure
•   In case of misuse and combined consumption with alcohol, the recommendations are similar to those 
for combating the use of illicit drugs (see Countermeasures to combat illicit drug-impaired driving).
Future needs of scientific investigations
•   Expand research on the impact of medicines (alone or in combination with other substances) on 
fitness to drive.
•   Develop procedures for the assessment of fitness to drive.
•   Assess the effectiveness of improved package information leaflets for moderately and severely 
impairing medicines.
•   Develop and evaluate new ways to influence patients’ intended and reported behaviour of 
driving under the influence of psychotropic medicines when advised not to drive during the first 
days or weeks of treatment.
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Annex 1: Overview of the estimated European prevalence of psychoactive substances in drivers
Inhabitants 
(million) negative amphetamines cocaine THC illicit opiates
benzodiaze-
pines Z-drugs
medicinal 
opiates and 
opioids
alcohol alcohol-drugs drugs-drugs
Northern 
Europe
DK   5.4 95.52 
94.72-96.2
0.02 
0-0.16
–
–
0.2 
0.09-0.43
–
–
0.47 
0.28-0.79
0.32 
0.17-0.59
0.79 
0.53-1.18
2.53 
2.02-3.15
0.1 
0.03-0.3
0.06 
0.02-0.24
FI   5.3 97.15 
96.58-97.63
0.05 
0.02-0.19
0.03 
0.01-0.16
0.04 
0.01-0.17
–
–
0.79 
0.56-1.13
0.36 
0.21-0.6
0.56 
0.37-0.85
0.64 
0.43-0.94
0.08 
0.03-0.23
0.29 
0.16-0.52
NO   4.7 97.03 
96.67- 97.36
0.06 
0.02-0.13
0.06 
0.03-0.14
0.48 
0.36-0.64
–
–
0.84 
0.67- 1.05
0.69 
0.54-0.88
0.16 
0.1-0.27
0.32 
0.23-0.46
0.07 
0.03-0.15
0.28 
0.19-0.42
SE   9.1 98.66 
98.34-98.92
0.07 
0.03-0.17
–
–
0.03 
0.01-0.12
–
–
0.19 
0.11-0.33
0.31 
0.2-0.48
0.63 
0.46- 0.86
NA NA 0.12 
0.06-0.25
Total N-EU  93.3 97.32 0.05 0.02 0.16 0.00 0.51 0.40 0.56 1.20 0.05 0.17
Eastern 
Europe
CZ  10.3 97.2 
96.39-97.33
0.36 
0.17-0.72
–
–
0.46 
0.25-0.86
–
–
0.62 
0.36-1.07
–
–
0.21 
0.08- 0.52
0.99 
0.65-1.53
0.05 
0.01-0.28
0.11 
0.03-0.38
HU  10.1 97.68 
97.04-98.18
–
–
0.04 
0.01-021
0.19 
0.08-0.44
–
–
1.5 
1.11-2.03
0.07 
0.02-0.26
0.11 
0.04-0.32
0.15 
0.06-0.38
–
–
0.27 
0.13-0.54
LT  3.4 94.49 
93.09-95.61
0.22 
0.07-0.66
–
–
–
–
–
–
1.41 
0.9 -2.23
–
–
–
–
3.86 
2.93-5.06
0.03 
0-0.36
–
–
PL  38.2 97.63 
97.11-98.05
0.05 
0.01-0.18
–
–
0.57 
0.38-0.85
0.09 
0.04-0.25
0.14 
0.06-0.31
–
–
0.03 
0.01-0.15
1.47 
1.14-1.9
–
–
0.02 
0-0.14
Total E-EU  96.7 97.57 0.09 0.01 0.47 0.06 0.52 0.02 0.08 1.10 0.01 0.07
Southern 
Europe
ES  44.5 85.15 
83.87-86.34
0.11 
0.04-0.3
1.49 
1.12-1.97
5.99 
5.22-6.87
0.05 
0.01-0.2
1.4 
1.05-1.87
–
–
0.19 
0.09-0.41
3.92 
3.3-4.66
1.14 
0.83-1.58
0.57 
0.36-0.89
IT  59.1 84.99 
82.95-86.32
–
–
1.25 
0.78-2.01
1.15 
0.7-1.89
0.3 
0.12-0.78
0.97 
0.57-1.57
–
–
0.53 
0.25-1.09
8.59 
7.19-10.23
1.01 
0.59-1.71
1.22 
0.75-1.97
PT  10.6 90.01 
89.04-90.91
–
–
0.03 
0.01-0.16
1.38 
1.07-1.8
0.15 
0.07-0.33
2.73 
2.27-3.29
–
–
0.11 
0.04-0.27
4.93 
4.29-5.64
0.42 
0.26-0.67
0.23 
0.12-0.44
Total S-EU 128.6 85.52 0.04 1.23 3.06 0.19 1.30 0.00 0.36 6.43 1.01 0.87
Western 
Europe
BE  10.6 89.35 
88.18-90.41
–
–
0.2 
0.09-0.43
0.35 
0.19- 0.64
0.09 
0.03-0.28
2.01 
1.57-2.59
0.22 
0.1-0.47
0.75 
0.5-1.13
6.42 
5.59-7.36
0.31 
0.16- 0.58
0.3 
0.16- 0.58
NL  16.4 94.49 
93.81-95.1
0.19 
0.1-0.36
0.3 
0.18-0.5
1.67 
1.34-2.07
0.01 
0-0.09
0.4 
0.25-0.62
0.04 
0.01-0.15
0.16 
0.08-0.32
2.15 
1.78-2.6
0.24 
0.13-0.42
0.35 
0.22-0.56
Total W-EU 181.4 92.46 0.12 0.26 1.15 0.04 1.03 0.11 0.39 3.83 0.27 0.33
Weighted European mean 500.0 92.57 0.08 0.42 1.32 0.07 0.90 0.12 0.35 3.48 0.37 0.39
Note: Prevalences in percentage; 95 % confidence intervals in italics.
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Annex 2:  Core substance list and equivalent analytical cut-off values
Substance Whole blood (ng/ml) Oral fluid (ng/ml)
Ethanol 0.1 g/l 0.082 g/l
6-acetylmorphine 10 16
7-aminoclonazepam 10 3.1
7-aminoflunitrazepam 8.5 1.0
Alprazolam 10 3.5
Amphetamine 20 360
Benzoylecgonine 50 95
Clonazepam 10 1.7
Cocaine 10 170
Codeine 10 94
Diazepam 140 5.0
Flunitrazepam 5.3 1.0
Lorazepam 10 1.1
3,4-methylenedioxyamphetamine (MDA) 20 220
3,4-methylenedioxy-N-ethylamphetamine (MDEA) 20 270
3,4-methylenedioxy-N-methylamphetamine (MDMA) 20 270
Methadone 10 22
Methamphetamine 20 410
Morphine 10 95
Nordiazepam 20 1.1
Oxazepam 50 13
Tetrahydrocannabinol (THC) 1.0 27
Tramadol 50 480
Zolpidem 37 10
Zopiclone 10 25
Note: THC-COOH cannot be detected in oral fluid with commonly available toxicological methods.
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Annex 3: List of DRUID deliverables
All deliverables can be downloaded from the DRUID project website (http://www.druid-project.eu).
No. Title Content
0.1.8 Final Report: work performed, main results 
and recommendations
Main results of the project and evidence based 
conclusions and recommendations relevant for EU and 
Member State policy makers
Work Package 1
1.1.1 Theoretical framework for substance effects 
on safe driving
Description of the theoretical framework and the 
methodology on how to integrate the results from the 
different study types (epidemiological research, 
experimental research, literature reviews) of WP1 and 
WP2
1.1.2.a Meta-analysis of empirical studies 
concerning the effects of alcohol on safe 
driving
Meta-analysis based on 450 experimental studies 
published until 2007 with a total number of 5 300 
findings of alcohol effects on driving performance, skills 
related to driving, social behaviour or mood
1.1.2.b Meta-analysis of empirical studies 
concerning the effects of medicines and 
illegal drugs including pharmacokinetics on 
safe driving
Meta-analysis of empirical studies on the effects of 
major medicines and major illicit drugs on driving 
performance and on skills related to driving. In 
addition, dose- and time-dependent impairment curves 
and concentration-dependent impairment curves are 
provided
1.1.2.c Psychomotor relevant performance
1. After single dose administration of 
opioids, narcoanalgesics and hallucinogens 
to drug-naïve subjects
2. In patients treated chronically with 
morphine or methadone/buprenorphine
Literature reviews on the effects of opioids, 
narcoanalgesics and hallucinogens on driving and skills 
related to driving. A distinction is made between the 
effects caused by single administration to drug-naïve 
subjects and patients under chronic treatment
1.2.1 Effects of stimulant drugs on actual and 
simulated driving
Experimental studies conducted according to a uniform 
study design (road tracking tests, car-following scenario 
and risk-taking scenario) designed to assess the effects 
of dexamphetamine and MDMA on actual or simulated 
driving performance: MDMA (25, 50 and 100 mg) 
before and after sleep deprivation, MDMA (100 mg) 
with and without alcohol (0.5 g/l), dexamphetamine 
(10 and 40 mg) before and after sleep deprivation, 
dexamphetamine (10 mg) with and without alcohol
1.2.2 Effects of medicinal drugs on actual and 
simulated driving
Experimental studies conducted according to a uniform 
study design (road tracking tests, car-following 
scenario) designed to assess the effects of medicines 
(zopiclone, hypnotics, alprazolam, Continuous Positive 
Airway Pressure (CPAP) treatment, codiliprane 
(codeine/paracetamol), dronabinol, opioid analgesics, 
risperidone) on driving performance
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No. Title Content
1.3.1 Risk estimations from different 
methodological approaches
Integration of the results of all epidemiological studies, 
experimental studies and meta-analyses conducted in 
DRUID. The psychoactive substances investigated in 
DRUID are classified with respect to prevalence and 
accident risk. Recommendations are given for alcohol, 
illicit drugs and medicines
1.4.1 Evaluation of legal measures to combat 
DUI/DUID
This report describes how driving under the influence of 
psychoactive substances can be combated effectively 
by legal interventions. Unlike the other deliverables, 
which are written from an experimental or 
epidemiological perspective, here a juridical 
perspective is taken
1.4.2 Per se limits: methods of defining cut-off 
values for zero tolerance
Recommendations for establishing cut-off levels for 
drugs in per se legislation for driving under the 
influence are made. Therefore, based on the authors’ 
experience, the experience in Member States and 
Norway, the results of DRUID and scientific literature, 
this report aims at giving pertinent considerations that 
might be of interest for nations which want to determine 
per se cut-off levels
Work Package 2
2.1.1 Prevalence of psychoactive substances in the 
general population
Analysis of trends in consumption of some frequently 
used medicines with effects on the central nervous 
system in a non-hospitalised EU population and the use 
of illicit drugs in standard age groups in Europe
2.1.2 Working paper ‘Uniform design and 
protocols for carrying out case–control 
studies’
This uniform design was developed aiming to assure a 
representativeness of roadside surveys that were 
implemented in order to determine prevalence of 
psychoactive substances use in traffic in different 
countries
2.2.1 Motives behind risky driving: driving under 
the influence of alcohol and drugs
The deliverable describes results of in-depth interviews 
of Swedish drivers driven under the influence of alcohol 
and drugs. The aim of the study was to explore motives 
behind DUI/DUID in Sweden
2.2.2. German smart-phone survey
Part I: Prevalence of psychoactive substances 
and consumption patterns in traffic, based on 
a smart-phone survey in Germany
Part II: Person-related characteristics of drug 
users and drug drivers compared to controls
The study was conducted in order to estimate 
prevalence of psychoactive substances within the 
German driving population and to identify preventive 
and encouraging circumstances of drug driving
2.2.3 Prevalence of alcohol and other 
psychoactive substances in drivers in 
general traffic
Part I: General results
Part II: Country reports
The main objective of this study was to gain solid 
knowledge concerning the use of psychoactive 
substances among drivers in European traffic. In total 
almost 50 000 randomly selected drivers in 13 
countries were involved. Saliva samples were collected 
using uniform method and equipment. Samples were 
analysed for 23 psychoactive substances
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No. Title Content
2.2.4 Prevalence study: main illicit psychoactive 
substances among all drivers involved in 
fatal road crashes in France
The deliverable presents results of evaluation of 
prevalence of drivers under the influence of alcohol and 
some illicit psychoactive substances for all drivers 
involved in fatal accidents in France, for responsible 
and for not responsible drivers. Prevalence was 
evaluated according to road user type, age and sex
2.2.5 Prevalence of alcohol and other 
psychoactive substances in injured and 
killed drivers
Results of prevalence study implemented in nine 
countries in two different populations (injured and killed 
drivers). Toxicological analyses were carried out on a 
total of 4 857 blood samples. Results served as 
reference data for the relative risk estimations
2.3.1 Relative accident risk of patients using 
psychotropic medicines in the Netherlands: 
a pharmacoepidemiological study
The aim of the case–control study presented in this 
deliverable was to assess the association between 
traffic accident risk and psychotropic medication 
exposure
2.3.2 Responsibility study: main illicit psychoactive 
substances among car drivers involved in 
fatal road crashes in France
The deliverable presents results of evaluation of relative 
risk of responsibility for fatal crashes while driving 
under influence of alcohol and some illicit psychoactive 
substances. The study was carried out in France
2.3.3 Relative risk of impaired drivers who were 
killed in motor vehicle accidents in Finland
The deliverable documents the results of a study carried 
out in Finland aiming to compare the relative risk of 
accident responsibility of non-impaired drivers versus 
that of killed drivers impaired by alcohol or some other 
legal psychoactive substance
2.3.4 Responsibility study: psychoactive 
substances among killed drivers in 
Germany, Lithuania, Hungary and Slovakia
Results of the study that aimed at analysing prevalence 
of substances used by killed drivers and estimating 
relative risk among fatally injured drivers responsible 
for fatal accident when driving under the influence of 
psychoactive substances
2.3.5 Risk of injury by driving with alcohol and 
other drugs
This deliverable presents results of studies implemented 
in nine countries aiming to assess the risk for a driver of 
being seriously injured or killed driving under the 
influence of psychoactive substances
2.4.1 Work Package 2 Synthesis report The report gives a compact overview of the results and 
conclusions of the Work Package 2
Work Package 3
3.1.1 Evaluation of oral fluid screening devices by 
TISPOL to harmonise European police 
requirements (ESTHER)
Methodology, implementation and results of practical 
evaluation of 13 oral fluid screening devices for 
roadside drugs detection. Evaluation was implemented 
by police officers under real conditions of enforcement 
activities. Based on the operation experience a set of 
Police User Requirements and Specifications (PURS) has 
been developed
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3.2.1 Protocol of the ‘Workshop on drug driving 
detection by means of oral fluid screening’
Compendium of presentations and conclusions of the 
DRUID workshop conducted on 23 August 2009 in 
Geneva aiming to reconcile objectives and methods of 
analytical evaluation of screening devices taking into 
account results of practical evaluation
3.2.2 Analytical evaluation of oral fluid screening 
devices and preceding selection procedures
Methodology, implementation and results of analytical 
evaluation of eight oral fluid screening devices 
preselected by police officers. Performance was 
assessed based on sensitivity, specificity, accuracy, 
positive predictive value and negative predictive value 
for individual substances
3.3.1 Cost–benefit analysis of drug driving 
enforcement by the police
An assessment of the economic societal profitability of 
(increased) enforcement against driving under the 
influence of drugs together with an assessment of which 
of the existing devices for such enforcement are 
profitable
Work Package 4
4.1.1 Review of existing classification efforts Compilation of the existing classification system on 
medicines according to their influence on driving 
performances. In this report, the past and current 
systems across Europe are described and compared
4.2.1 Establishment of criteria for a European 
categorisation system for medicines and 
driving
Development of input for the establishment of a 
European categorisation system for medicines and 
driving. A proposal on the criteria and the 
methodology, based on
expert consensus
4.3.1 Establishment of framework for 
classification/categorisation and labelling of 
medicinal drugs and driving
Evaluation of available data of medicines on the 
European market and subsequent assignment of 
categories and labels on medicines and driving. 
Development of fact sheets and patient-oriented 
information. Development of a methodology to 
continuously update the categorisation and labelling 
system
4.4.1 Classification of medicinal drugs and 
driving: a synthesis report
Report presents all results and conclusions of DRUID 
Work Package 4 in a compact form
Work Package 5
5.1.1 State of the art on driver rehabilitation: 
literature analysis & provider survey
The deliverable aims at providing updated 
comprehensive knowledge on European driver 
rehabilitation (DR) best practices and comprises 
identification of different types of DUI/DUID offenders, 
options for assessment including different available 
approaches, existing rehabilitation programmes in and 
outside Europe, their scientific evidence regarding 
traffic safety criteria and research on addiction 
treatment
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5.2.1 Good practice: in-depth analysis on 
recidivism reasons & analysis of change 
process and components in driver 
rehabilitation courses
Reasons for recidivism concerning traffic rules offence 
analysed on a basis of a case–control study. Group 
comparison and regression analysis implemented.
Analysis of change process and components of DR 
courses was carried out by means of a questionnaire 
survey developed on the basis of the TTM (Trans-
Theoretical Model of Change) supplemented by the 
Diamond of Change
5.2.2 Development of an integrated evaluation 
instrument for driver rehabilitation measures
Presentation of DRET (Driver Rehabilitation Evaluation 
Tool), an instrument for evaluation of rehabilitation 
measures. Two modules (DRET-L and DRET-P) can be 
applied for evaluation of DR systems (L) and single 
programmes (P).
5.2.3 Quality management systems established 
along with driver rehabilitation schemes
The deliverable explains relevance and importance of 
quality management (QM) systems for DR activities, 
describes existing QM systems and evaluates them
5.2.4 Validation of existing driver rehabilitation 
measures
This deliverable contains recommendations with regard 
to DR measures developed on the basis of assessment 
and validation of 90 European DR programmes
Work Package 6
6.1.1 State-of-the-art on withdrawal of driving 
licence: results of a questionnaire survey
The deliverable provides the comprehensive database 
of the legal systems as well as the practices in 
European countries with respect to withdrawal and 
re-granting of driving licenses where a withdrawal was 
a sanction against impaired driving, i.e. driving under 
influence of alcohol, illicit drugs or medicines
6.2.1 Recommendations on withdrawal Recommendations on driving licence withdrawal/
conditional withdrawal strategies and accompanying 
measures
Work Package 7
7.1.1 Review of guidelines, booklets, and other 
resources: state of the art
Review of the state of the art of existing information 
campaigns regarding psychoactive substances, as well 
as the documented effectiveness of those campaigns
7.2.1 Recommendations for improving medical 
guidelines for assessing fitness to drive in 
patients who use psychotropic medicines
Evaluation of existing medical guidelines for assessing 
fitness to drive within the framework of Council 
Directive 91/439/EEC on driving licenses. Overview 
of the current European regulations with regard to the 
assessment of fitness to drive and on driving 
performance in case patients use psychotropic 
medicines. Recommendations to improve prescribing 
and dispensing guidelines and procedures for assessing 
fitness to drive
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7.2.2 Guidelines & professional standards
Report and CD with examples of ICT 
supported protocols for prescribing and 
dispensing of medicines affecting driving 
performance, and for informing patients 
who use psychoactive substances other than 
medicines
Prescribing and dispensing guidelines for selecting 
driving impairing medicines. Application practice 
guidelines and protocols in clinical decision support 
systems that general practitioners and pharmacists can 
use daily. ICT-supported protocols. Tools developed 
within DRUID to train general practitioners and 
pharmacists. Recommendations for future development 
of prescribing and dispensing guidelines
7.3.1 Prototypes of booklets, posters, messages for 
risk communication including a script for a 
TV-clip
Online experts survey on criteria for designing 
prototype documents for information regarding 
psychoactive substances and driving. Prototype 
documents for different target groups and analysis on 
how the documents were elaborated
7.3.2 Main DRUID results to be communicated to 
different target groups
Description of the risk communication theoretic frame. 
Assessment of pictograms in communicating risk to 
patients who drive under the influence of medicines. 
Overview of the main DRUID results with regard to the 
interests of the following target groups: (1) general 
public, (2) drivers as patients, (3) young drivers, (4) 
physicians and pharmacists and (5) policymakers at EU 
and national levels
7.4.1 Training manual for physicians and 
pharmacists on medicinal drugs and driving
A general overview and outlines of the relevant parts in 
the training courses for physicians and pharmacists 
(background, objectives, structure). Overview of 
decision-supporting ICT and non-ICT tools for assisting 
physicians and pharmacists in their daily prescribing 
and dispensing processes
7.4.2 Report on the implementation, evaluation 
and new technologies of practice guidelines 
and information materials
Evaluation of protocols and guidelines implementation 
(target group — healthcare professionals) using 
integrated (ICT) tools and non-integrated tools. Results 
of studies implemented in cooperation with healthcare 
professionals in three countries
7.4.3 DRUID outcomes and risk communication to 
young drivers
Results of an effort made to define appropriate risk 
communication measures for young drivers. A 
representative sample of 15- to 24-year-olds in 
Germany was interviewed about (a) their personal 
experiences and attitudes concerning driving under the 
influence of drugs, alcohol and/or medicines, (b) 
knowledge about impact of psychoactive substances 
and motivation to process risk communication messages 
and (c) media use patterns and preferences for risk 
message contents and channels
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